CA1145750A - Octahydro-2h-pyrrolo (3,4,-g) quinolines - Google Patents
Octahydro-2h-pyrrolo (3,4,-g) quinolinesInfo
- Publication number
- CA1145750A CA1145750A CA000403807A CA403807A CA1145750A CA 1145750 A CA1145750 A CA 1145750A CA 000403807 A CA000403807 A CA 000403807A CA 403807 A CA403807 A CA 403807A CA 1145750 A CA1145750 A CA 1145750A
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- trans
- mixture
- formula
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229940111121 antirheumatic drug quinolines Drugs 0.000 title abstract description 5
- 150000003248 quinolines Chemical class 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 73
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 13
- 239000000543 intermediate Substances 0.000 claims abstract description 9
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 claims abstract description 7
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims abstract description 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims abstract 15
- 238000000034 method Methods 0.000 claims description 21
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 230000007062 hydrolysis Effects 0.000 claims description 4
- 238000006460 hydrolysis reaction Methods 0.000 claims description 4
- 229910052987 metal hydride Inorganic materials 0.000 claims description 4
- 150000004681 metal hydrides Chemical class 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- GZWNUORNEQHOAW-UHFFFAOYSA-M potassium;2-aminoacetate Chemical compound [K+].NCC([O-])=O GZWNUORNEQHOAW-UHFFFAOYSA-M 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims 2
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 239000012434 nucleophilic reagent Substances 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 abstract description 17
- 102000003946 Prolactin Human genes 0.000 abstract description 14
- 108010057464 Prolactin Proteins 0.000 abstract description 14
- 229940097325 prolactin Drugs 0.000 abstract description 14
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract description 7
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 abstract description 6
- 206010034010 Parkinsonism Diseases 0.000 abstract description 5
- 239000003136 dopamine receptor stimulating agent Substances 0.000 abstract description 5
- 208000027089 Parkinsonian disease Diseases 0.000 abstract description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract description 3
- 230000028327 secretion Effects 0.000 abstract description 3
- 229940052760 dopamine agonists Drugs 0.000 abstract description 2
- 239000003112 inhibitor Substances 0.000 abstract description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 70
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 66
- 239000000203 mixture Substances 0.000 description 64
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 46
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 42
- 238000006243 chemical reaction Methods 0.000 description 41
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 39
- 239000011541 reaction mixture Substances 0.000 description 37
- 229960001701 chloroform Drugs 0.000 description 35
- -1 7-substituted-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo[3,4-g]quinolines Chemical class 0.000 description 33
- 239000000243 solution Substances 0.000 description 32
- 125000000217 alkyl group Chemical group 0.000 description 31
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 30
- 238000001704 evaporation Methods 0.000 description 29
- 230000008020 evaporation Effects 0.000 description 29
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 239000002904 solvent Substances 0.000 description 21
- 229920006395 saturated elastomer Polymers 0.000 description 19
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 18
- 239000000284 extract Substances 0.000 description 18
- 239000012299 nitrogen atmosphere Substances 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 238000010992 reflux Methods 0.000 description 15
- 239000011780 sodium chloride Substances 0.000 description 15
- 238000004809 thin layer chromatography Methods 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 13
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 13
- 241000700159 Rattus Species 0.000 description 13
- 239000011877 solvent mixture Substances 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 239000012280 lithium aluminium hydride Substances 0.000 description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 10
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 10
- 238000001953 recrystallisation Methods 0.000 description 10
- 239000000470 constituent Substances 0.000 description 9
- 150000002688 maleic acid derivatives Chemical class 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 8
- 239000004471 Glycine Substances 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 239000002026 chloroform extract Substances 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 229940117975 chromium trioxide Drugs 0.000 description 6
- WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 6
- GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 150000002081 enamines Chemical class 0.000 description 5
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- 239000011976 maleic acid Substances 0.000 description 5
- 238000006722 reduction reaction Methods 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- VFICJPDIBDJAGL-UHFFFAOYSA-N (4-oxocyclohexyl) benzoate Chemical compound C=1C=CC=CC=1C(=O)OC1CCC(=O)CC1 VFICJPDIBDJAGL-UHFFFAOYSA-N 0.000 description 4
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 4
- POTIYWUALSJREP-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroquinoline Chemical compound N1CCCC2CCCCC21 POTIYWUALSJREP-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical class SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 4
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 150000001350 alkyl halides Chemical class 0.000 description 4
- 239000000908 ammonium hydroxide Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000002178 crystalline material Substances 0.000 description 4
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 4
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 4
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 4
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 4
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 239000002024 ethyl acetate extract Substances 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000002524 organometallic group Chemical group 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- GRQLNUPVDJMLQN-UHFFFAOYSA-N (2-oxo-3,4,5,6,7,8-hexahydro-1h-quinolin-6-yl) benzoate Chemical compound C1CC(NC(=O)CC2)=C2CC1OC(=O)C1=CC=CC=C1 GRQLNUPVDJMLQN-UHFFFAOYSA-N 0.000 description 2
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229910010084 LiAlH4 Inorganic materials 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 2
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 2
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 2
- QSKWJTXWJJOJFP-UHFFFAOYSA-N chloroform;ethoxyethane Chemical compound ClC(Cl)Cl.CCOCC QSKWJTXWJJOJFP-UHFFFAOYSA-N 0.000 description 2
- WGXZDYPGLJYBJW-UHFFFAOYSA-N chloroform;propan-2-ol Chemical compound CC(C)O.ClC(Cl)Cl WGXZDYPGLJYBJW-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 2
- 229960003147 reserpine Drugs 0.000 description 2
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- LYPGDCWPTHTUDO-UHFFFAOYSA-M sodium;methanesulfinate Chemical compound [Na+].CS([O-])=O LYPGDCWPTHTUDO-UHFFFAOYSA-M 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000028838 turning behavior Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- SCVWCVDUCPPXST-UHFFFAOYSA-N (1-methyl-2-oxo-3,4,5,6,7,8-hexahydroquinolin-6-yl) benzoate Chemical compound CN1C(=O)CCC(C2)=C1CCC2OC(=O)C1=CC=CC=C1 SCVWCVDUCPPXST-UHFFFAOYSA-N 0.000 description 1
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 description 1
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 description 1
- IEWJKCCBASHQIW-UHFFFAOYSA-N 1-benzyl-3,4,4a,5,6,7,8,8a-octahydro-2h-quinolin-6-ol Chemical compound C1C(O)CCC2C1CCCN2CC1=CC=CC=C1 IEWJKCCBASHQIW-UHFFFAOYSA-N 0.000 description 1
- LXQDIWJHYSPHSE-UHFFFAOYSA-N 1-propyl-3,4,4a,5,6,7,8,8a-octahydro-2h-quinolin-6-ol Chemical class C1C(O)CCC2N(CCC)CCCC21 LXQDIWJHYSPHSE-UHFFFAOYSA-N 0.000 description 1
- VMJNTFXCTXAXTC-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole-5-carbonitrile Chemical group C1=C(C#N)C=C2OC(F)(F)OC2=C1 VMJNTFXCTXAXTC-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- 125000003541 2-chlorobenzoyl group Chemical group ClC1=C(C(=O)*)C=CC=C1 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- QKNPGPYFWRUKRM-UHFFFAOYSA-N 3,4,5,6,7,8-hexahydro-1h-quinolin-2-one Chemical compound N1C(=O)CCC2=C1CCCC2 QKNPGPYFWRUKRM-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- VZMIUFKFIRLVEQ-UHFFFAOYSA-N 5h-pyrrolo[3,4-g]quinoline Chemical class C1=CC=C2CC3=CN=CC3=CC2=N1 VZMIUFKFIRLVEQ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 244000118350 Andrographis paniculata Species 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical group OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- 101100037762 Caenorhabditis elegans rnh-2 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010067991 Decapitation Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000001287 Galactorrhea Diseases 0.000 description 1
- 206010017600 Galactorrhoea Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- HJOIEQOGEUEMRY-BTJKTKAUSA-N OC(=O)\C=C/C(O)=O.C1=CC=C2CC3=CN=CC3=CC2=N1 Chemical compound OC(=O)\C=C/C(O)=O.C1=CC=C2CC3=CN=CC3=CC2=N1 HJOIEQOGEUEMRY-BTJKTKAUSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910020667 PBr3 Inorganic materials 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 230000000397 acetylating effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- YTIVTFGABIZHHX-UHFFFAOYSA-L acetylenedicarboxylate(2-) Chemical compound [O-]C(=O)C#CC([O-])=O YTIVTFGABIZHHX-UHFFFAOYSA-L 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical group BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- JOYKCMAPFCSKNO-UHFFFAOYSA-N chloro benzenesulfonate Chemical compound ClOS(=O)(=O)C1=CC=CC=C1 JOYKCMAPFCSKNO-UHFFFAOYSA-N 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000000911 decarboxylating effect Effects 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000727 fraction Substances 0.000 description 1
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycine anhydride Natural products [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- KKLGDUSGQMHBPB-UHFFFAOYSA-N hex-2-ynedioic acid Chemical compound OC(=O)CCC#CC(O)=O KKLGDUSGQMHBPB-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- JCYWCSGERIELPG-UHFFFAOYSA-N imes Chemical class CC1=CC(C)=CC(C)=C1N1C=CN(C=2C(=CC(C)=CC=2C)C)[C]1 JCYWCSGERIELPG-UHFFFAOYSA-N 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical class [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- XHXXWWGGXFUMAJ-UHFFFAOYSA-N methanethiol;sodium Chemical compound [Na].SC XHXXWWGGXFUMAJ-UHFFFAOYSA-N 0.000 description 1
- AGJSNMGHAVDLRQ-HUUJSLGLSA-N methyl (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,3-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound SC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(=O)OC)CC1=CC=C(O)C(C)=C1C AGJSNMGHAVDLRQ-HUUJSLGLSA-N 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- YGAMIEYKXHAVBP-UHFFFAOYSA-N molecular hydrogen;hydrochloride Chemical compound Cl.[H][H] YGAMIEYKXHAVBP-UHFFFAOYSA-N 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000005440 p-toluyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C(*)=O)C([H])([H])[H] 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 238000006894 reductive elimination reaction Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000003461 sulfonyl halides Chemical class 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Abstract of the Disclosure Described herein are novel compounds of the formula IC
wherein R1 is H or (C1-C3) alkyl-CO;
R2 is H, benzyl or C1-C3 alkyl; and R3 is H, COO(C1-C3)alkyl, COOH, or CH2X1 wherein X1 is OH, Cl, OSO2(C1-C3)alkyl, OSO2to1yl, or OSO2phenyl;
with the proviso that both R1 and R3 can not be H when R2 is C1-C3 alkyl; and their salts.
These compounds are useful as intermediates in preparing octahydro-2H-pyrrolo [3,4-g] quinolines of the formula wherein R1 is H or C1-C3 alkyl;
R2 ic C1-C3 alkyl or allyl;
R3 is H or CH2X wherein X is CN, CONH2, SO2CH3, SCH3 or OCH3. The compounds of formula I
are useful as dopamine agonists, and particularly as inhibitors of prolactin secretion and in treatment of Parkinsonism.
wherein R1 is H or (C1-C3) alkyl-CO;
R2 is H, benzyl or C1-C3 alkyl; and R3 is H, COO(C1-C3)alkyl, COOH, or CH2X1 wherein X1 is OH, Cl, OSO2(C1-C3)alkyl, OSO2to1yl, or OSO2phenyl;
with the proviso that both R1 and R3 can not be H when R2 is C1-C3 alkyl; and their salts.
These compounds are useful as intermediates in preparing octahydro-2H-pyrrolo [3,4-g] quinolines of the formula wherein R1 is H or C1-C3 alkyl;
R2 ic C1-C3 alkyl or allyl;
R3 is H or CH2X wherein X is CN, CONH2, SO2CH3, SCH3 or OCH3. The compounds of formula I
are useful as dopamine agonists, and particularly as inhibitors of prolactin secretion and in treatment of Parkinsonism.
Description
S~SO
X-5060F~
OCTAHYDRO--2H-PYRROLO [ 3, 4-g ] QUINOLINES
This invention, in one aspect, prcvides trans-dl-5 and 7-substituted-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo[3,4-g]quinolines of the following structure R N~2 T T T
1 0 \3~3~4~ S- I
wherein Rl is H or Cl-C3 alkyl;
R is Cl-C3 alkyl or allyl;
R is H or CH2X wherein X is C~, CONH2, SO2CH3, SCH3 or OCH3~ and ~ he pharmaceutically-acceptable acid addition salts thereof.
The compounds of formula I can be prepared by reacting a compound of the formula / \
2s ,I, ,~R2 t ,/
R~ Id , ~1~5750 )B --2--wherein Rl,is (Cl-C3)alkyl-CO;
R ~is H, Cl-C3 alkyl, or allyl;
R is H or CH2Y;
S Y is Cl, Br, OSO2phenyl, O-tosyl, or - S2(Cl-C3)alkyl;
with base to provide the compounds of formula I wherein Rl is H;
optionally followëd by reacting with an alkyl halide to obtain the compounds of formula I
where Rl is Cl-C3 alkyl;
where R is H followed by reacting with an alkyl or allyl halide or reductive alkylation with an appropriate aldehyde and metal hydride to obtain the compounds of formula I where R2 is Cl-C3 alkyl or allyl;
followed by reacting the compound of formula Id where R3 is CH2Y with sodium methylate, methylmercap~ sodium salt, sodium cyanide, or sodium methanesulfinate, to obtain the o~x~nds of fornLla I where R3 is CH2X where X is, respectively OCH3, SCH3, CN, or S02CH3; and opt~lly followed by reacting the o~npounds of formLla I
where R3 is ~ CN with hydration to obtain the o~pounds of formLla I
where R3 is CH2oONH2;and where desired, formmg pharmaceutically acoq~ble acid addition salts of the om~ounds of fonn~a I.
The compounds of formula I, and the process for preparing same, are also disclosed and are claimed, in Canadian Patent Application.330,551, filed June 26, 1979, of which this application is a divisional.
In the above formula, the ring junction (the 4a, 8a bond) is trans and the compounds are obtained as a racemic pair. The two stereoisomers constituting the racemate can be drawn as structures Ia and Ib below .
1~14575(~
X-5060~3 _3_ tsa 7 9~ ~e\~/ \ \R3 Rl-~2 t I and R~ 2 ~ T
\3~3,4~ ~ \3~,~3~4~ ~
Ia - Ib In addition, introduction of a substituent at C-7 (R3 is other than H) creats a new chiral center and the compounds of that structure exist as 4 stereoisomers in two racemic pairs. The synthetic procedures to be set forth herein yield a single predominant racemate consisting of the 4a~,7~,8aa isomer and its mirror image, the 4a~,7~,8a~ isomer.
Resolution of this racemate into its component diastereoisomers can be readily accomplished by methods currently available in the art. Regardless of the structure currently assigned to a given isomer or racemate, this invention provides com-pounds of the above formula having dopaminergic activity, whether in pure form as a single di-astereoisomer or admixed with one, or more, less active or even inactive diastereoisomers.
Also within the scope of this invention are novel intermediates of the formula ,I, ~I-R~
~I, ,1 IC
R~
wherein Rl is ~ or (Cl-C3)alkyl-CO;
R2 is H, benzyl or Cl-C3 alkyl; and R3 is H, COO(Cl-C3)alkyl, COOH, or CH~Xl wherein Xl is OH, Cl, OSO2(Cl-C3)alkyl, OSO2 tolyl, or OSO2phenyl; 1 3 with the proviso that both R and R can not be H when R2 is Cl-C3 alkyl; and their salts.
In the above formulas, the term "Cl-C3 alkyl" includes methyl, ethyl, n-propyl and iso-propyl.
The pharmaceutically-acceptahle acid addition salts of this invention include salts derived from inorganic acids such as: hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydriodic acid, nitrous acid, phosphoric acid and the like, as well as salts der~ved from nontoxic organic acids such as ali-phatic mono and dicarboxylic acids, phenyl-sub-stituted alkanoic acids, hydroxy alkanoic and ~ ,~
alkandioic acids, aromatic acids, aliphatic and aromatic sulfonic acid. Such pharmaceutically-ac-ceptable salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, meta-phosphate, pyrophosphate, chloride, bromide, iodide, fluoride, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chloro-benzoate, methylben20ate, dinitrobenzoate, hydroxy-benzoate, methoxybenzoate, phthalate, terephthalate, benzenesulfonate, toluenesulfonate, chlorobenzene-sulfonate, xylenesulfonate, phenylacetate, phenyl-propionate, ~henylbutyrate, citrate 9 lac~ate, ~-hydroxybutyrate, glycollate, malate, tartrate, methanesulfonate, propanesulfonate, naphthalene-l-sulfonate, naphthalene-2-sulfonate and the like ~alts.
The intermediates coming within the scope of Fon~a Ic rorm useful salts with all varieties of acids, not just non-toxic acids, and these salts are used for reaction and purification purposes.
Illustrative compounds falling within the scope of formula I include:
trans-dl-2j5-dimethyl-7-methylmercapto-methyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo[3,4-glquinoline sulfate -7S(~
trans-dl-2,5-dimethyl-7-methoxymethyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo[3,4-g]quinoline sulfate trans-dl-5-methyl-4,4a,5,6,7,8,8a,9-octa-hydro-2H-pyrrolo[3,4-g]quinoline hydrochloride trans-dl-5-isopropyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolol3,4-g]quinoline trans-dl-2-methyl-5-n-propyl-7-methyl-sulfonylmethyl-4,4a,5,6,7,8,8a,9-octahydro-2H-O pyrrolo[3,4-g]quinoline maleate trans-dl-5-ethyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo[3,4-g]quinoline trans-dl-5-allyl-4,4a,5,6,7,8,8a,9-octa-hydro-2H-pyrrolot3,4-g~quinoline.
. The compounds of fo~mula I in which R3 is H are prepared according to the procedure outlined in ~eaction Scheme I below. In Reaction Scheme I, only one stereoisomer has been drawn for convenience, but it should be remembered that each decahydro-quinoline and each octahydropyrrolot3,4-g]quinoline exists as a racemate. In addition, R2 is other than H.
, ' 11~57SO
X-5~60r~ -7-Reaction Scheme I
I~ ' pyrrol idine acrylamide ac i d cata I ys~ / \ /-o co z Z-c~I
III H
R2X I NaH
V R2 I z HC I IV
X-5060F~
OCTAHYDRO--2H-PYRROLO [ 3, 4-g ] QUINOLINES
This invention, in one aspect, prcvides trans-dl-5 and 7-substituted-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo[3,4-g]quinolines of the following structure R N~2 T T T
1 0 \3~3~4~ S- I
wherein Rl is H or Cl-C3 alkyl;
R is Cl-C3 alkyl or allyl;
R is H or CH2X wherein X is C~, CONH2, SO2CH3, SCH3 or OCH3~ and ~ he pharmaceutically-acceptable acid addition salts thereof.
The compounds of formula I can be prepared by reacting a compound of the formula / \
2s ,I, ,~R2 t ,/
R~ Id , ~1~5750 )B --2--wherein Rl,is (Cl-C3)alkyl-CO;
R ~is H, Cl-C3 alkyl, or allyl;
R is H or CH2Y;
S Y is Cl, Br, OSO2phenyl, O-tosyl, or - S2(Cl-C3)alkyl;
with base to provide the compounds of formula I wherein Rl is H;
optionally followëd by reacting with an alkyl halide to obtain the compounds of formula I
where Rl is Cl-C3 alkyl;
where R is H followed by reacting with an alkyl or allyl halide or reductive alkylation with an appropriate aldehyde and metal hydride to obtain the compounds of formula I where R2 is Cl-C3 alkyl or allyl;
followed by reacting the compound of formula Id where R3 is CH2Y with sodium methylate, methylmercap~ sodium salt, sodium cyanide, or sodium methanesulfinate, to obtain the o~x~nds of fornLla I where R3 is CH2X where X is, respectively OCH3, SCH3, CN, or S02CH3; and opt~lly followed by reacting the o~npounds of formLla I
where R3 is ~ CN with hydration to obtain the o~pounds of formLla I
where R3 is CH2oONH2;and where desired, formmg pharmaceutically acoq~ble acid addition salts of the om~ounds of fonn~a I.
The compounds of formula I, and the process for preparing same, are also disclosed and are claimed, in Canadian Patent Application.330,551, filed June 26, 1979, of which this application is a divisional.
In the above formula, the ring junction (the 4a, 8a bond) is trans and the compounds are obtained as a racemic pair. The two stereoisomers constituting the racemate can be drawn as structures Ia and Ib below .
1~14575(~
X-5060~3 _3_ tsa 7 9~ ~e\~/ \ \R3 Rl-~2 t I and R~ 2 ~ T
\3~3,4~ ~ \3~,~3~4~ ~
Ia - Ib In addition, introduction of a substituent at C-7 (R3 is other than H) creats a new chiral center and the compounds of that structure exist as 4 stereoisomers in two racemic pairs. The synthetic procedures to be set forth herein yield a single predominant racemate consisting of the 4a~,7~,8aa isomer and its mirror image, the 4a~,7~,8a~ isomer.
Resolution of this racemate into its component diastereoisomers can be readily accomplished by methods currently available in the art. Regardless of the structure currently assigned to a given isomer or racemate, this invention provides com-pounds of the above formula having dopaminergic activity, whether in pure form as a single di-astereoisomer or admixed with one, or more, less active or even inactive diastereoisomers.
Also within the scope of this invention are novel intermediates of the formula ,I, ~I-R~
~I, ,1 IC
R~
wherein Rl is ~ or (Cl-C3)alkyl-CO;
R2 is H, benzyl or Cl-C3 alkyl; and R3 is H, COO(Cl-C3)alkyl, COOH, or CH~Xl wherein Xl is OH, Cl, OSO2(Cl-C3)alkyl, OSO2 tolyl, or OSO2phenyl; 1 3 with the proviso that both R and R can not be H when R2 is Cl-C3 alkyl; and their salts.
In the above formulas, the term "Cl-C3 alkyl" includes methyl, ethyl, n-propyl and iso-propyl.
The pharmaceutically-acceptahle acid addition salts of this invention include salts derived from inorganic acids such as: hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydriodic acid, nitrous acid, phosphoric acid and the like, as well as salts der~ved from nontoxic organic acids such as ali-phatic mono and dicarboxylic acids, phenyl-sub-stituted alkanoic acids, hydroxy alkanoic and ~ ,~
alkandioic acids, aromatic acids, aliphatic and aromatic sulfonic acid. Such pharmaceutically-ac-ceptable salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, meta-phosphate, pyrophosphate, chloride, bromide, iodide, fluoride, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chloro-benzoate, methylben20ate, dinitrobenzoate, hydroxy-benzoate, methoxybenzoate, phthalate, terephthalate, benzenesulfonate, toluenesulfonate, chlorobenzene-sulfonate, xylenesulfonate, phenylacetate, phenyl-propionate, ~henylbutyrate, citrate 9 lac~ate, ~-hydroxybutyrate, glycollate, malate, tartrate, methanesulfonate, propanesulfonate, naphthalene-l-sulfonate, naphthalene-2-sulfonate and the like ~alts.
The intermediates coming within the scope of Fon~a Ic rorm useful salts with all varieties of acids, not just non-toxic acids, and these salts are used for reaction and purification purposes.
Illustrative compounds falling within the scope of formula I include:
trans-dl-2j5-dimethyl-7-methylmercapto-methyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo[3,4-glquinoline sulfate -7S(~
trans-dl-2,5-dimethyl-7-methoxymethyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo[3,4-g]quinoline sulfate trans-dl-5-methyl-4,4a,5,6,7,8,8a,9-octa-hydro-2H-pyrrolo[3,4-g]quinoline hydrochloride trans-dl-5-isopropyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolol3,4-g]quinoline trans-dl-2-methyl-5-n-propyl-7-methyl-sulfonylmethyl-4,4a,5,6,7,8,8a,9-octahydro-2H-O pyrrolo[3,4-g]quinoline maleate trans-dl-5-ethyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo[3,4-g]quinoline trans-dl-5-allyl-4,4a,5,6,7,8,8a,9-octa-hydro-2H-pyrrolot3,4-g~quinoline.
. The compounds of fo~mula I in which R3 is H are prepared according to the procedure outlined in ~eaction Scheme I below. In Reaction Scheme I, only one stereoisomer has been drawn for convenience, but it should be remembered that each decahydro-quinoline and each octahydropyrrolot3,4-g]quinoline exists as a racemate. In addition, R2 is other than H.
, ' 11~57SO
X-5~60r~ -7-Reaction Scheme I
I~ ' pyrrol idine acrylamide ac i d cata I ys~ / \ /-o co z Z-c~I
III H
R2X I NaH
V R2 I z HC I IV
2 0 NaCNBH3 ~ _ \ HzSO- / I~
VI RZ VII RZ
(CHs) 2NCH(OZ ~ ~ ) z ~CHaCO) zO K g l yc i nate O~ / \-/ \
(CHs) 2NC~ H\N/
VIII RZ
.,, ~ ~ ' 11~5750 X-50~0Ps --8--S ',i,,~ `r~
IX X
In the above reaction scheme, Z-CO is an acyl pro-tecting group in which Z i5 (Cl-C3)alkyl, (C2-C3)-alkenyl, ~C2-C3)alkynyl, (C5-C6)cycloalkyl, phenyl or.substituted phenyl wherein the substituting group can be methyl, methoxy, chloro and the like, at any position of the phenyl ring. Illustratively, Z-CO
can be acetyl, propionyl, butyryl, propiolyl, acrylyl, benzoyl, p-toluyl, o-chlorobenzoyl, or m-methoxybenzoyl.
Acetals of dimethylformamide useful in producing compound VIII in Reaction Scheme I (and compound XV in Reaction Scheme II below) have the general formula (CH3)2N-CH-(OZ'')2 in which Z " is (Cl-C8)alkyl, ~C5 C6)cycloalkyl, (C3-C4)alkenyl, (C3-C4)alkynyl and the like. We prefer to employ one of the commercially available acetals of di-methylformamide; i.e.: the dimethyl, diethyl,diisopropyl, dibutyl, dicyclohexyl, dipropyl or dineopentyl acetals.
.
~-so60n _9_ In accordance with Reaction Scheme I, 4-acyloxycyclohexanone (II) prepared by the procedure of E.R.H. Jones and F. Sondheimer, J. Chem. Soc., 615, (1949) is reacted with pyrrolidine in the presence of an acid catalyst to yield a pyrrolidine enamine. This enamine is in turn reacted with acrylamide to produce a mixture of dl-6-acyloxy-
VI RZ VII RZ
(CHs) 2NCH(OZ ~ ~ ) z ~CHaCO) zO K g l yc i nate O~ / \-/ \
(CHs) 2NC~ H\N/
VIII RZ
.,, ~ ~ ' 11~5750 X-50~0Ps --8--S ',i,,~ `r~
IX X
In the above reaction scheme, Z-CO is an acyl pro-tecting group in which Z i5 (Cl-C3)alkyl, (C2-C3)-alkenyl, ~C2-C3)alkynyl, (C5-C6)cycloalkyl, phenyl or.substituted phenyl wherein the substituting group can be methyl, methoxy, chloro and the like, at any position of the phenyl ring. Illustratively, Z-CO
can be acetyl, propionyl, butyryl, propiolyl, acrylyl, benzoyl, p-toluyl, o-chlorobenzoyl, or m-methoxybenzoyl.
Acetals of dimethylformamide useful in producing compound VIII in Reaction Scheme I (and compound XV in Reaction Scheme II below) have the general formula (CH3)2N-CH-(OZ'')2 in which Z " is (Cl-C8)alkyl, ~C5 C6)cycloalkyl, (C3-C4)alkenyl, (C3-C4)alkynyl and the like. We prefer to employ one of the commercially available acetals of di-methylformamide; i.e.: the dimethyl, diethyl,diisopropyl, dibutyl, dicyclohexyl, dipropyl or dineopentyl acetals.
.
~-so60n _9_ In accordance with Reaction Scheme I, 4-acyloxycyclohexanone (II) prepared by the procedure of E.R.H. Jones and F. Sondheimer, J. Chem. Soc., 615, (1949) is reacted with pyrrolidine in the presence of an acid catalyst to yield a pyrrolidine enamine. This enamine is in turn reacted with acrylamide to produce a mixture of dl-6-acyloxy-
3,4,5,6,7,8-hexahydro-2(1H)-quinolinone and dl-6-acyloxy-3,4,4a,5,6,7-hexahydro-2(lH)-quinolinone represented by formula III, the dotted lines in-dicating the alternative positions of the double bond.
Next, the acidic nitrogen (acidic since it is alpha to a carbonyl group) is alkylated with an alkyl halide R2X wherein R2 has the same meaning as hereinabove and X is a halogen such as Cl, Br or I, in the presence of sodium hydride to yield a mixture of dl-l-(Cl-C3) alkyl (or allyl or benzyl)-6-acyloxy-3,4,5,6,7,8-hexahydro-2(lH)-quinolinone and its ~8 isomer (IV). Reduction of this amide with lithium aluminum hydride or other suitable organo-metallic reducing agent yields a mixture of dl-l-(Cl-C3) alkyl (or allyl or benzyl)-6-hydroxy-1,2,3,4,5,6,7,8-octahydroquinoline and its ~8 isomer. In this reaction mixture, conditions are encountered which serve to hydrogenolyze the acyloxy group to a hydroxyl group at C-6. The dl-l-(Cl-C3)-alkyl (or allyl or benzyl)-6-hydroxyoctahydroquino-line mixture i5 next converted to an ammonium salt by treatment with hydrochloric acid, and the ammonium . .
x-s~. ~or -lo-salt is then reduced with sodium cyanoborohydride to yield trans-dl-l- (Cl-C3)alkyl (or allyl or benzyl)-6-hydroxydecahydroquinoline (VI). Next, the trans-dl-l- (Cl-C3 alkyl, allyl, or benzyl)-6-hydroxy-5 decahydro~uinoline ~VI) is oxidized using, preferably,chromium trioxide in acetic acid, to yield the corresponding 6-oxo compound (VII). By adapting the procedure o~ Zav'yalof et al. C.A., 80, 59815z(1974), Izv. Akad. N uk. SSSR. Ser. Khim 2572-7 (1973), this 10 6-oxo compound (VII) is reacted with dimethylform-amide dimethylacetal to yield a 7-dimethylamino-methylene-6-oxo-derivative (VIII). Reaction of this derivative with potassium glycinate followed by treatment of the thus formed intermediate product 15 with acetic anhydride yields a tricyclic derivative, trans-dl-2-acetyl-5- [(Cl-C3)alkyl, allyl or benzyl)]-
Next, the acidic nitrogen (acidic since it is alpha to a carbonyl group) is alkylated with an alkyl halide R2X wherein R2 has the same meaning as hereinabove and X is a halogen such as Cl, Br or I, in the presence of sodium hydride to yield a mixture of dl-l-(Cl-C3) alkyl (or allyl or benzyl)-6-acyloxy-3,4,5,6,7,8-hexahydro-2(lH)-quinolinone and its ~8 isomer (IV). Reduction of this amide with lithium aluminum hydride or other suitable organo-metallic reducing agent yields a mixture of dl-l-(Cl-C3) alkyl (or allyl or benzyl)-6-hydroxy-1,2,3,4,5,6,7,8-octahydroquinoline and its ~8 isomer. In this reaction mixture, conditions are encountered which serve to hydrogenolyze the acyloxy group to a hydroxyl group at C-6. The dl-l-(Cl-C3)-alkyl (or allyl or benzyl)-6-hydroxyoctahydroquino-line mixture i5 next converted to an ammonium salt by treatment with hydrochloric acid, and the ammonium . .
x-s~. ~or -lo-salt is then reduced with sodium cyanoborohydride to yield trans-dl-l- (Cl-C3)alkyl (or allyl or benzyl)-6-hydroxydecahydroquinoline (VI). Next, the trans-dl-l- (Cl-C3 alkyl, allyl, or benzyl)-6-hydroxy-5 decahydro~uinoline ~VI) is oxidized using, preferably,chromium trioxide in acetic acid, to yield the corresponding 6-oxo compound (VII). By adapting the procedure o~ Zav'yalof et al. C.A., 80, 59815z(1974), Izv. Akad. N uk. SSSR. Ser. Khim 2572-7 (1973), this 10 6-oxo compound (VII) is reacted with dimethylform-amide dimethylacetal to yield a 7-dimethylamino-methylene-6-oxo-derivative (VIII). Reaction of this derivative with potassium glycinate followed by treatment of the thus formed intermediate product 15 with acetic anhydride yields a tricyclic derivative, trans-dl-2-acetyl-5- [(Cl-C3)alkyl, allyl or benzyl)]-
4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo[3,4-g]quino-line ~IX). Removal of the acetyl group at N-2 with base yields the dopamine agonist (X) when R2 is 20 ~Cl-C3~alkyl or allyl, or a u~eful intermediate when R is benzyl.
Those compounds in which Rl is Cl-C3 alkyl are prepared from compound X by taking advantage of the acidic hydrogen in the pyrrole ring and reacting 25 an anionic salt thereof, prepared from sodium hydride or other suitable base, with an alkyl halidP, Rl X
where Rl is (Cl-C3) alkyl or allyl and X is Cl, Br or Those compounds in which R2 i~ benzyl can 30 be transformed into compounds in which R2 is ~Cl-C3)alkyl or allyl as follows: the benzyl group 11'~5750 can be removed by reductive cleavage or by treatment with cyanogen bromide to yield, eventually, a com-pound in which R2 is H. The usual conditions for removing an N-benzyl group are hydrogen with a palladium-on~carbon catalyst or reaction with cyano-gen bromide followed by reductive (Zn and acetic acid) cleavage of the N-cyano compound. This debenzylated compound can then be al~ylated with an allyl or a lower alkyl halide, or alternatively it may be reductively alkylated using acetaldehyde, propionaldehyde or other aldehyde with a metal hydride, such as sodium cyanoborohydride.
Compounds according to formula I above in which R3 is other than H are prepared according to a slightly different, but comparable, synthetic route illustrated in Reaction Scheme II below. As in Reaction Scheme I, the synthetic procedure is illustrated for convenience with respect to a single stereoisomer (referring to the bridgehead config-uration) the 4aB,8a~ isomer.
il~5750 ~-5060B
Reaction Scheme II
O
/-\ RZNH2 ~ / \ ~ \t-COOZ~
~ CH2=C-COOZ' I CH2Hal O-CO-Z XI R
II - acid H \ BH4 lo t ~ r , z OH / OH
XIIII R2 \ ~ XII
. pyridine-HCI RZ
CrOs ~ /
/ \-/ \ , (CHs) 0=~ COOZ ~
H IN O= /-\~/-\ COOZ' XIV R (CH3)2NCH= ~\ /i\N/
K glycinate acetic anhydrTde \ /
H= / \-/ \t-COOZ' / hydrlYSis ACN~cH=~
H~c t T r R2 H \~ XVI
~:, R2 XVII
~-5060B
wherein Z and Z'' have the same significance as in Reaction Scheme I, Hal is chloro or bromo and Z' is part of a readily hydrolyzable group Z'O-CO including (Cl-C2)al~yl, phenyl subs-tituted (Cl-C2)alkyl, illus-tratively benzyl, phenethyl, p-methoxybenzyl, methyl, ethyl and others.
In accordance with the Reaction Scheme II, a 4-acyloxycyclohexanone (II) is reacted with an a-halomethylacrylate ester, for illustrative pur-poses, the ethyl ester, and an amine, RNH2, wherein Ris Cl-C3 alkyl, allyl or benzyl. The product of this reaction is a mixture of dl-l-substituted-3-ethoxy-carbonyl-6-acyloxy-1,2,3,4,5,6,7,8-octahydroquinoline and dl-l-substituted-3-ethoxycarbonyl-6-acyloxy-1,2,3,4,4a,5,6,7-octahydroquinoline represented by XI
in which the dotted line indicates the alternate positions of the double bond. The hydrochloride salts of these isomers are prepared and the resulting mixture reduced with sodium cyanoborohydride to yield trans-dl-1-substitu~ed-3-ethoxycarbonyl-6-acyloxy-decahydroquinoline (XII). Hydrolysis of this diester to yield a 6-hydroxy-3-carboxylic acid followed by reesterification of the carboxylic acid group with ethanol or other alcohol in the presence of acid yields trans-dl-1-substituted-3-e~hoxycarbonyl-6-hydroxydecahydroquinoline txIII). Oxidation of the hydroxy group with Sarett's Reagent (pyridine hydro-chloride and chromium trioxide) produces the cor-responding 6-oxo compound (XIV). Treatment of this 6-oxo derivative with dimethylform~mide dimethyl-X-5060s acetal results in reaction at C-7 (adjacent to the keto group) to give trans-dl-l-substituted-3-ethoxy-carbonyl-6-oxo-7-(dimethylaminomethylene)decahydro-quinoline (XV). Reaction of this derivative with potassium glycinate followed by a treatment of the intermediate product with acetic anhydride gives the tricyclic derivative, trans-dl-2-acetyl-5-substi-tuted-7-ethoxycarbonyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo~3,4-g]quinoline (XVI). Hydrolysis with sodium ethoxide in ethanol yields the NH compound (XVII).
The octahydropyrrolo[3,4-g]quinoline of Formula XVI represents a single isomer. The mirror image of XVI is produced concomitantly and is in-cluded within the scope of this invention. Webelieve, based upon analogy with the D-ergolines, that the diastereoisomer XVI as drawn is the isomer having dopamine ~gonist activity. The trans-dl racemate, which contains XVI and its mirror image, is of course useful as a dopamine agonist, even though most of the desired activi~y resides in one of its component stereoisomers.
Compounds according to XVI above in which R2 is methyl or benzyl can be transformed into compounds in which R2 is ethyl, allyl or n-propyl by reaction with cyanogen bromide. The intermediate
Those compounds in which Rl is Cl-C3 alkyl are prepared from compound X by taking advantage of the acidic hydrogen in the pyrrole ring and reacting 25 an anionic salt thereof, prepared from sodium hydride or other suitable base, with an alkyl halidP, Rl X
where Rl is (Cl-C3) alkyl or allyl and X is Cl, Br or Those compounds in which R2 i~ benzyl can 30 be transformed into compounds in which R2 is ~Cl-C3)alkyl or allyl as follows: the benzyl group 11'~5750 can be removed by reductive cleavage or by treatment with cyanogen bromide to yield, eventually, a com-pound in which R2 is H. The usual conditions for removing an N-benzyl group are hydrogen with a palladium-on~carbon catalyst or reaction with cyano-gen bromide followed by reductive (Zn and acetic acid) cleavage of the N-cyano compound. This debenzylated compound can then be al~ylated with an allyl or a lower alkyl halide, or alternatively it may be reductively alkylated using acetaldehyde, propionaldehyde or other aldehyde with a metal hydride, such as sodium cyanoborohydride.
Compounds according to formula I above in which R3 is other than H are prepared according to a slightly different, but comparable, synthetic route illustrated in Reaction Scheme II below. As in Reaction Scheme I, the synthetic procedure is illustrated for convenience with respect to a single stereoisomer (referring to the bridgehead config-uration) the 4aB,8a~ isomer.
il~5750 ~-5060B
Reaction Scheme II
O
/-\ RZNH2 ~ / \ ~ \t-COOZ~
~ CH2=C-COOZ' I CH2Hal O-CO-Z XI R
II - acid H \ BH4 lo t ~ r , z OH / OH
XIIII R2 \ ~ XII
. pyridine-HCI RZ
CrOs ~ /
/ \-/ \ , (CHs) 0=~ COOZ ~
H IN O= /-\~/-\ COOZ' XIV R (CH3)2NCH= ~\ /i\N/
K glycinate acetic anhydrTde \ /
H= / \-/ \t-COOZ' / hydrlYSis ACN~cH=~
H~c t T r R2 H \~ XVI
~:, R2 XVII
~-5060B
wherein Z and Z'' have the same significance as in Reaction Scheme I, Hal is chloro or bromo and Z' is part of a readily hydrolyzable group Z'O-CO including (Cl-C2)al~yl, phenyl subs-tituted (Cl-C2)alkyl, illus-tratively benzyl, phenethyl, p-methoxybenzyl, methyl, ethyl and others.
In accordance with the Reaction Scheme II, a 4-acyloxycyclohexanone (II) is reacted with an a-halomethylacrylate ester, for illustrative pur-poses, the ethyl ester, and an amine, RNH2, wherein Ris Cl-C3 alkyl, allyl or benzyl. The product of this reaction is a mixture of dl-l-substituted-3-ethoxy-carbonyl-6-acyloxy-1,2,3,4,5,6,7,8-octahydroquinoline and dl-l-substituted-3-ethoxycarbonyl-6-acyloxy-1,2,3,4,4a,5,6,7-octahydroquinoline represented by XI
in which the dotted line indicates the alternate positions of the double bond. The hydrochloride salts of these isomers are prepared and the resulting mixture reduced with sodium cyanoborohydride to yield trans-dl-1-substitu~ed-3-ethoxycarbonyl-6-acyloxy-decahydroquinoline (XII). Hydrolysis of this diester to yield a 6-hydroxy-3-carboxylic acid followed by reesterification of the carboxylic acid group with ethanol or other alcohol in the presence of acid yields trans-dl-1-substituted-3-e~hoxycarbonyl-6-hydroxydecahydroquinoline txIII). Oxidation of the hydroxy group with Sarett's Reagent (pyridine hydro-chloride and chromium trioxide) produces the cor-responding 6-oxo compound (XIV). Treatment of this 6-oxo derivative with dimethylform~mide dimethyl-X-5060s acetal results in reaction at C-7 (adjacent to the keto group) to give trans-dl-l-substituted-3-ethoxy-carbonyl-6-oxo-7-(dimethylaminomethylene)decahydro-quinoline (XV). Reaction of this derivative with potassium glycinate followed by a treatment of the intermediate product with acetic anhydride gives the tricyclic derivative, trans-dl-2-acetyl-5-substi-tuted-7-ethoxycarbonyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo~3,4-g]quinoline (XVI). Hydrolysis with sodium ethoxide in ethanol yields the NH compound (XVII).
The octahydropyrrolo[3,4-g]quinoline of Formula XVI represents a single isomer. The mirror image of XVI is produced concomitantly and is in-cluded within the scope of this invention. Webelieve, based upon analogy with the D-ergolines, that the diastereoisomer XVI as drawn is the isomer having dopamine ~gonist activity. The trans-dl racemate, which contains XVI and its mirror image, is of course useful as a dopamine agonist, even though most of the desired activi~y resides in one of its component stereoisomers.
Compounds according to XVI above in which R2 is methyl or benzyl can be transformed into compounds in which R2 is ethyl, allyl or n-propyl by reaction with cyanogen bromide. The intermediate
5-cyano derivative can be reductively cleaved (zinc plus acetic acid) to yield a compound in which R2 is H. In addition, the benzyl group can be removed by hydrogenation with palladium-on-carbon to yield those intermediates in which R2=H. Alkylation of those compounds in which R2 is H can be accomplished by reaction with an alkyl halide, R2Cl, R2Br or R2I.
Alternatively, the secondary amine can be reacted with acetadehyde, acrolein, or propionaldehyde under reducing conditions (NaBH3CN) to yield an N-ethyl, N-allyl or N-n-propyl derivative.
The dopamine agonists of formula I in which R3 is other than H; i.e. those compounds in which R3 is CH2X wherein X is CN, OCH3, SCH3, SO2CH3 or CO;NH2, are prepared according to Reaction Scheme III helow ' , ' ' ' ,', ' ' .
- ; .
.~ .
li45750 x-50~0r~
Reaction Scheme III
CH~r COOZ ' LiAlH4 XVII
\ /
1 o f tosy l-C I SOC I 2 (Cl -Cs) a I ky I -SO2C I PC 15 pheny I -SO~C I POC i 3 PBr3 \ /
CH ~ \Nr XIX
NaCN
2 5 CHsSNa CH~ONa \ CHsSO~Na CH ~ \N/r R
X-5060~
wherein Z' and R have the same significance as before, Y is a "leaving" group: Cl, Br, OSO2phenyl, O-tosyl or SO2(Cl-C3)alkyl, R2 is H, SO2phenyl, tosyl or SO2tCl-C3)alkyl, and X is CN, SCH3, OCH3 or SO2C~3. The acetyl group of a compound according to XVI in Reaction Scheme II is hydrolyzed with sodium ethoxide in ethanol or sodium methoxide in methanol to yield a desacetyl derivative. The carboalkoxy group is then reduced with a metal hydride such as LiAlH4 to an hydroxymethyl group, thus providing a trans-dl-5-substituted-7-hydroxymethyl-4,4a,5,6,-7,8,8a,9-octahydro-2H-pyrrolo[3,4-g]quinoline (XVIII). The hydroxyl can be replaced with a chlorine or bromine lea~ing group and the resulting chloro-methyl or bromomethyl compound reacted with NaCN toyield a compound in which R3 is C~2-CN. Other leaving groups--groups readily replaced by a nucleophilic reagent--such as the mesyloxy, p-tosyloxy, benzenesulfonyloxy and the like groups lwhen X in formula I, Ia or Ib or Y in formula XIX, is OSO2~Cl-C3)alkyl, OSO2phenyl or OSO2tolyl]
can be produced by acylation of the hydroxy group with a sulfonyl halide. Reaction of the thus-produced compound with sodium methylate, methyl-mercaptan sodium salt, sodium cyanide, sodiummethanesulfinate or other basic salts of methanol, methylmercaptan yields compounds according to formula I, Ia or Ib in which ~3 is CH2X and X is SCH3, OCH3, CN or SO2CH3. Compound~s in which X is CONH2 are prepared by hydration of the corresponding cyano compound.
11~5750 Compounds represented by formulas I, Ia and Ib, in which R2 is H and by form~las IX, and X above have two centers of asymmetry, the ring junction carbons at 8a and 4a. Thus, the compounds can occur as two racemates, ordinarily denominated as the trans-dl racemate and the cis-dl racemate. It is believed, however, according to the best evidence from 13C NMR spectral data of the maleate salt of the compound according to Formula X above wherein R2 is benzyl, that the cyanoborohydride reduction (going from V to VI in Reaction Scheme I) yields a trans-fused decahydroquinoline. While the arguments for the trans configuration based upon 13C NMR spectral data are compelling, an X-ray crystallographic investigation has also been carried out on the nicely crystalline enaminoketone (VIII) in which R2 is methyl, the precursor of the pyrrole (X). This X-ray analysis indicated clearly that the ring junction is trans. Thus, only the trans racemate is prepared by the synthetic procedures disclosed herein and the compounds of formula I are preferably represented as the trans-dl steroisomers Ia and Ib above in which R3 is H. Resolution of this racemate into its optical antipodes can be accomplished by procedures known to those skilled in the art, and the individual trans-d and trans-l isomers are included within the scope of this invention.
When R3 is other than H, a third chiral center is introduced at C-7, thereby doubling, at least in theory, the number of isomers produced by 575(~
Reaction Schemes II and III. However, it is pres-ently believed that the configuration of the C-7 group is "trans" to that of the 8a hydrogen. Thus in Ia above, R3 when it is other than H, has a beta configuration with the Ba hydrogen having an alpha configuration. In the mirror image Ib, the 8a hydrogen is beta and the C-7 substituent alpha.
Thus the dl-trans-7-subYtituted octahydropyrrolo-[3,4-g]quinolines of formula I are provided sub-stantially as a single racemate.
In addition, it is apparent from an in-spection of the dl-trans-l(substituted)-6-keto decahydroquinoline (VII) that reaction with di-methylformamide dimethylacetal could take place at either C-5 or C-7 since both these carbons are ortho to the ketone group and are thus "activated". The same X-ray crystallographic analysis of the enamine (VIII) clearly indicated that reaction had taken place at C-7 rather than C-5. ~ence, the final tricyclic compounds IX, X, XVI and I are the linear pyrrolo[3,4-g]quinolines rather than the angular tricyclic compounds (which would be named as 4,4a,-5,6,7,8,8a,9-octahydro-1~-pyrrolo[2,3-i]quinolines).
This invention is further illustrated by the following specific examples.
1145 ;J50 ~-50~0B
STARTING MAmERIALS
Example A
Preparation of trans-dl-2-Acetyl 5-methyl-4,4a,5, 6,7,8,8a,9-octahydro-2H-pyrrold B,4-g]quino-line.
A reaction mixture was prepared from 52 g.
of 4-benzoyloxycyclohexanone, 30 ml. of pyrrolidine, a few crystals of p-toluene sulfonic acid mono-hydrate, and 1000 ml. of benzene. The reaction mixture was heated to refluxing temperature under a nitrogen atmosphere for one hour in an apparatus equipped with a Dean-Stark water trap. ~he reaction mixture was then cooled and the solvent and other ~olatile materials removed by evaporation in vacuo.
The residue, comprising the pyrrolidine enamine of 4-benzoyloxycyclohexanone formed in the above re-action was dissolved without further purification in 1000 ml. of dioxane. 42.6 g. of acrylamide were added. ~his new reaction mixture was heated under a nitrogen atmosphere at reflux temperature for twenty-one hours. Thin-layer chromatography of the reaction mixture indicated one major spot. The reaction mixture was cooled and the volatile con-stituents removed by evaporation in vacuo. Achloroform solution of the residue comprising 6-benzoyloxy-3,4,5,6,7,8-hexahydro-lH-quinolin-2~one and the isomeric product 6-benzoyloxy-3,4,4a,5,-
Alternatively, the secondary amine can be reacted with acetadehyde, acrolein, or propionaldehyde under reducing conditions (NaBH3CN) to yield an N-ethyl, N-allyl or N-n-propyl derivative.
The dopamine agonists of formula I in which R3 is other than H; i.e. those compounds in which R3 is CH2X wherein X is CN, OCH3, SCH3, SO2CH3 or CO;NH2, are prepared according to Reaction Scheme III helow ' , ' ' ' ,', ' ' .
- ; .
.~ .
li45750 x-50~0r~
Reaction Scheme III
CH~r COOZ ' LiAlH4 XVII
\ /
1 o f tosy l-C I SOC I 2 (Cl -Cs) a I ky I -SO2C I PC 15 pheny I -SO~C I POC i 3 PBr3 \ /
CH ~ \Nr XIX
NaCN
2 5 CHsSNa CH~ONa \ CHsSO~Na CH ~ \N/r R
X-5060~
wherein Z' and R have the same significance as before, Y is a "leaving" group: Cl, Br, OSO2phenyl, O-tosyl or SO2(Cl-C3)alkyl, R2 is H, SO2phenyl, tosyl or SO2tCl-C3)alkyl, and X is CN, SCH3, OCH3 or SO2C~3. The acetyl group of a compound according to XVI in Reaction Scheme II is hydrolyzed with sodium ethoxide in ethanol or sodium methoxide in methanol to yield a desacetyl derivative. The carboalkoxy group is then reduced with a metal hydride such as LiAlH4 to an hydroxymethyl group, thus providing a trans-dl-5-substituted-7-hydroxymethyl-4,4a,5,6,-7,8,8a,9-octahydro-2H-pyrrolo[3,4-g]quinoline (XVIII). The hydroxyl can be replaced with a chlorine or bromine lea~ing group and the resulting chloro-methyl or bromomethyl compound reacted with NaCN toyield a compound in which R3 is C~2-CN. Other leaving groups--groups readily replaced by a nucleophilic reagent--such as the mesyloxy, p-tosyloxy, benzenesulfonyloxy and the like groups lwhen X in formula I, Ia or Ib or Y in formula XIX, is OSO2~Cl-C3)alkyl, OSO2phenyl or OSO2tolyl]
can be produced by acylation of the hydroxy group with a sulfonyl halide. Reaction of the thus-produced compound with sodium methylate, methyl-mercaptan sodium salt, sodium cyanide, sodiummethanesulfinate or other basic salts of methanol, methylmercaptan yields compounds according to formula I, Ia or Ib in which ~3 is CH2X and X is SCH3, OCH3, CN or SO2CH3. Compound~s in which X is CONH2 are prepared by hydration of the corresponding cyano compound.
11~5750 Compounds represented by formulas I, Ia and Ib, in which R2 is H and by form~las IX, and X above have two centers of asymmetry, the ring junction carbons at 8a and 4a. Thus, the compounds can occur as two racemates, ordinarily denominated as the trans-dl racemate and the cis-dl racemate. It is believed, however, according to the best evidence from 13C NMR spectral data of the maleate salt of the compound according to Formula X above wherein R2 is benzyl, that the cyanoborohydride reduction (going from V to VI in Reaction Scheme I) yields a trans-fused decahydroquinoline. While the arguments for the trans configuration based upon 13C NMR spectral data are compelling, an X-ray crystallographic investigation has also been carried out on the nicely crystalline enaminoketone (VIII) in which R2 is methyl, the precursor of the pyrrole (X). This X-ray analysis indicated clearly that the ring junction is trans. Thus, only the trans racemate is prepared by the synthetic procedures disclosed herein and the compounds of formula I are preferably represented as the trans-dl steroisomers Ia and Ib above in which R3 is H. Resolution of this racemate into its optical antipodes can be accomplished by procedures known to those skilled in the art, and the individual trans-d and trans-l isomers are included within the scope of this invention.
When R3 is other than H, a third chiral center is introduced at C-7, thereby doubling, at least in theory, the number of isomers produced by 575(~
Reaction Schemes II and III. However, it is pres-ently believed that the configuration of the C-7 group is "trans" to that of the 8a hydrogen. Thus in Ia above, R3 when it is other than H, has a beta configuration with the Ba hydrogen having an alpha configuration. In the mirror image Ib, the 8a hydrogen is beta and the C-7 substituent alpha.
Thus the dl-trans-7-subYtituted octahydropyrrolo-[3,4-g]quinolines of formula I are provided sub-stantially as a single racemate.
In addition, it is apparent from an in-spection of the dl-trans-l(substituted)-6-keto decahydroquinoline (VII) that reaction with di-methylformamide dimethylacetal could take place at either C-5 or C-7 since both these carbons are ortho to the ketone group and are thus "activated". The same X-ray crystallographic analysis of the enamine (VIII) clearly indicated that reaction had taken place at C-7 rather than C-5. ~ence, the final tricyclic compounds IX, X, XVI and I are the linear pyrrolo[3,4-g]quinolines rather than the angular tricyclic compounds (which would be named as 4,4a,-5,6,7,8,8a,9-octahydro-1~-pyrrolo[2,3-i]quinolines).
This invention is further illustrated by the following specific examples.
1145 ;J50 ~-50~0B
STARTING MAmERIALS
Example A
Preparation of trans-dl-2-Acetyl 5-methyl-4,4a,5, 6,7,8,8a,9-octahydro-2H-pyrrold B,4-g]quino-line.
A reaction mixture was prepared from 52 g.
of 4-benzoyloxycyclohexanone, 30 ml. of pyrrolidine, a few crystals of p-toluene sulfonic acid mono-hydrate, and 1000 ml. of benzene. The reaction mixture was heated to refluxing temperature under a nitrogen atmosphere for one hour in an apparatus equipped with a Dean-Stark water trap. ~he reaction mixture was then cooled and the solvent and other ~olatile materials removed by evaporation in vacuo.
The residue, comprising the pyrrolidine enamine of 4-benzoyloxycyclohexanone formed in the above re-action was dissolved without further purification in 1000 ml. of dioxane. 42.6 g. of acrylamide were added. ~his new reaction mixture was heated under a nitrogen atmosphere at reflux temperature for twenty-one hours. Thin-layer chromatography of the reaction mixture indicated one major spot. The reaction mixture was cooled and the volatile con-stituents removed by evaporation in vacuo. Achloroform solution of the residue comprising 6-benzoyloxy-3,4,5,6,7,8-hexahydro-lH-quinolin-2~one and the isomeric product 6-benzoyloxy-3,4,4a,5,-
6,7-hexahydro-lH-quinolin-2-one was chroma~ographed over 350 g. of"Flrisil"* using chloroform containing * Trademark for a hard, porous, granular activated magnesium silicate, used in chromatography.
11'.~s5750 increasing quantities of ethanol (0 to 2 percent) as the eluant. Fractions found to contain 6-benzoyl-oxy-3,4,5,6,7,8-hexahydro-lH-quinolin-2-one and its isomer by thin-layer chromatography were combined and the solvent removed therefrom in vacuo. The re-sulting residue was crystallized by triturating with hexane to yield a crystalline mixture of 6-benzoyl-oxy-3,4,5,6,7,8-hexahydro-lH-quinolin-2-one and the corresponding 3,4,4a,5,6,7-hexahydro derivative.
The mixture melted in the range 130-150C. after recrystallization from an ether-hexane solvent mixture.
Analysis: Calculated: C, 70.83; H, 6.32;
N, 5.16;
Found: C, 71.05; H, 6.19, N, 5.33.
NMR of the product isolated above in-dicated that the mixture contained about 60 percent 24 of 6-benzoyloxy-3,4,5,6,7,8-hexahydro-lH-quino-lin-2-one and 40% of the 3,4,4a,5,6,7-hexahydro isomer.
46.5 g. of the above isomer mixture were dissolved in 400 ml. of tetrahydrofuran (THF).
80 ml. of methyl iodide were added and the resulting mixture cooled in an ice-water bath. 9.6 g. of sodium hydride (as a 50 percent suspension in mineral oil) were added in portions. After all of the sodium hydride suspension had been added, the cooling bath was removed and the reaction mixture :
ll~S7~0 X-5060s stirred at ambient temperature under a nitrogen atmosphere for about 4 hours. The reaction mixture was then diluted with water and the aqueous mixture thoroughly extracted with chloroform. The chloro-form extracts were combined and the combinedextracts washed with saturated aqueous sodium chloride and dried. The chloroform was removed by evaporation to dryness in vacuo leaving as a residue an orange oil weighing 47.3 g. Recrystallization from an e~her-hexane solvent mixture yielded crystals of l-methyl-6-benzoyloxy-3,4,5,6,7,8-hexahydro-2(lH)-quinolinone and the corresponding 3,4,4a,5,6,7-hexahydro isomer.
Analysis: Calculated: C, 71.56; H, 6.71; N, 4.91;
Found: C, 71.33; H, 6.90; N~ 4.67.
Following the above procedure, 59 g. of a mixture of Ç-benzoyloxy-3,4,5,6,7,8-hexahydro-2(lH)-quinolinone and 6-benzoyloxy-3,4,4a,5,6,-
11'.~s5750 increasing quantities of ethanol (0 to 2 percent) as the eluant. Fractions found to contain 6-benzoyl-oxy-3,4,5,6,7,8-hexahydro-lH-quinolin-2-one and its isomer by thin-layer chromatography were combined and the solvent removed therefrom in vacuo. The re-sulting residue was crystallized by triturating with hexane to yield a crystalline mixture of 6-benzoyl-oxy-3,4,5,6,7,8-hexahydro-lH-quinolin-2-one and the corresponding 3,4,4a,5,6,7-hexahydro derivative.
The mixture melted in the range 130-150C. after recrystallization from an ether-hexane solvent mixture.
Analysis: Calculated: C, 70.83; H, 6.32;
N, 5.16;
Found: C, 71.05; H, 6.19, N, 5.33.
NMR of the product isolated above in-dicated that the mixture contained about 60 percent 24 of 6-benzoyloxy-3,4,5,6,7,8-hexahydro-lH-quino-lin-2-one and 40% of the 3,4,4a,5,6,7-hexahydro isomer.
46.5 g. of the above isomer mixture were dissolved in 400 ml. of tetrahydrofuran (THF).
80 ml. of methyl iodide were added and the resulting mixture cooled in an ice-water bath. 9.6 g. of sodium hydride (as a 50 percent suspension in mineral oil) were added in portions. After all of the sodium hydride suspension had been added, the cooling bath was removed and the reaction mixture :
ll~S7~0 X-5060s stirred at ambient temperature under a nitrogen atmosphere for about 4 hours. The reaction mixture was then diluted with water and the aqueous mixture thoroughly extracted with chloroform. The chloro-form extracts were combined and the combinedextracts washed with saturated aqueous sodium chloride and dried. The chloroform was removed by evaporation to dryness in vacuo leaving as a residue an orange oil weighing 47.3 g. Recrystallization from an e~her-hexane solvent mixture yielded crystals of l-methyl-6-benzoyloxy-3,4,5,6,7,8-hexahydro-2(lH)-quinolinone and the corresponding 3,4,4a,5,6,7-hexahydro isomer.
Analysis: Calculated: C, 71.56; H, 6.71; N, 4.91;
Found: C, 71.33; H, 6.90; N~ 4.67.
Following the above procedure, 59 g. of a mixture of Ç-benzoyloxy-3,4,5,6,7,8-hexahydro-2(lH)-quinolinone and 6-benzoyloxy-3,4,4a,5,6,-
7-hexahydro-2~lH)-quinolinone were reacted with n-propyl iodide in the presence of sodium hydride to yield l-n-propyl-6-benzoyloxy-3,4,5,6,7,8-hexa-hydro-2(lH~-quinolinone and the corresponding 3,4,4a,5,6,7-hexahydro isomer. The compounds were purified by chromatography over "Florisil~l using an ether-chloroform solvent mixture as the eluant.
Also following the above procedure, a mixture of the l-benzyl-6~benzoyloxyhexahydro-2(lH)-quinolinones was prepared by substituting benzyl bromide for methyl iodide.
ll~S7SO`
A solution of 47.3 g. of a mixture of 1-methyl-6-benzoyloxy-3,4,5,6,7,8-hexahydro- 2 (lH) -quinolinone and the corresponding 3,4,4a,5,6,7-hexahydro isomer as obtained above were dissolved in 800 ml. of THF and the solution cooled to about 0C.
20 g. of lithium aluminum hydride were added thereto in portions and the resulting mixture refluxed for four hours under a nitrogen atmosphere. The reaction mixture was cooled and excess lithium aluminum hydride destroyed by the addition of ethyl acetate.
10~ sodium hydroxide was then added and the mixture diluted with water to decompose any organometallics - present. The aqueous mixture was extracted several times with a chloroform-isopropanol solvent mixture.
The organic extracts were combined and the combined extracts washed with saturated aqueous sodium chloride and then dried. Evaporation of the solvent yielded as a residue a mixture of the enamines--l-methyl-6-hydroxy-1,2,3,4,5,6,7,8-octahydroquino-line and 1-methyl-6-hydroxy-1,2,3,4,4a,5,6,7-octahydroqu$nol~ne--formed in the above reaction.
(The lithium aluminum hydride reduction served to remove the benzoyl group at C-6 as a benzyl alcohol moiety, leaving a free hydroxyl in that position of the ring). The above residue, without further purification, was dissolved in about 300 ml. of ether and the ethereal solution saturated with gaseous hydrogen chloride, thus forming the hydro-chloride salt of the enamine mixture. The ether was removed by decantation and the residue dissolved in .
, a mixture of 200 ml. of THF and 50 ml. of methanol.
This solution was cooled in an ice water bath. 12 g. of sodium cyanoborohydride were added with cooling and stirring. After all of the cyano-borohydride had been added, the reaction mixture wasstirred for another 60 minutes and then poured over a mixture of ice and lN aqueous hydrochloric acid.
The acidic aqueous solution was extracted with chloroform and the chloroform extract discarded.
The solution was then made basic with 14N aqueous ammonium hydroxide. Trans-dl-l-methyl-6-hydroxy-decahydroquinoline formed in the above reaction, being insoluble in the alkaline medium, separated and was extracted several times with a chloroform-isopropanol solvent mixture. The combined extracts were washed with saturated aqueous sodium chloride and then dried. Evaporation of the solvent yielded 15 g. of trans-dl-1-methyl-6-hydroxydecahydroquino-line.
Following the above sequence of reactions, a mixtùre of l-n-propyl-6-benzoyloxy-3,4,5,6,7,8-hexahydro-2(1H)-quinolinone and the corresponding 3,4,4a,5,6,7-hexahydro isomer were first reduced with lithium aluminum hydride to yield a mixture of ~4a and ~8 1-n-propyl-6-hydroxyoctahydroquinolines which was converted by treatment with ethereal hydrogen chloride to the enamine hydrochloride.
Reduction of this intermediate enamine hydrochloride with sodium cyanoborohydride yielded trans-dl-1-n-propyl-6-hydroxydecahydroquinoline (56 g. of starting material yielded 30 g. of product). Also following the above proceduxe, l-benzyl-6-benzoyl-oxy-3,4,5,6,7,8-hexahydro-2(lH)-quinolinone in admixture with l-benzyl-6-benzoyloxy-3,4,4a,5,-6,7-h~xahydro-2(lH)-quinolinone was reduced with lithium aluminum hydride to yield the corresponding l-benzyl-6-hydroxy-1,2,3,4,5,6,7,8-octahydroquino-line and l-benzyl-6-hydroxy-1,2,3,4,4a,5,6,7-octahydroquinoline as a mixture, treatment of which with ethereal hydrogen hydrochloride yielded the enamine salt. Reduction of the enamine salt with sodium cyanoborohydride gave 1-benzyl-6-hydroxydeca-hydroquinoline (65 g. of starting mixture yielded 49.6 g. of final product).
Fifteen grams of trans-dl-l-methyl-6-hydroxydecahydroquinoline were dissolved in 250 ml.
of 6N aqueous sulfuric acid. The solution was cooled in an ice-water bath. A solution of 9 g. of chromium trioxide in 60 ml. of 6N aqueous sulfuric acid were added thereto with stirring in dropwise fashion over a 10-minute period. The cooling bath was removed and the reaction mixture stirred for an additional 60 minutes at ambient temperature. The excess oxidizing agent was decomposed by adding isopropanol to the reaction mixture. The reaction mixture was next poured over ice and the acidic aqueous olution made basic with 14N aqueous ammonium hydroxide. trans-dl-l-Methyl-6-oxodeca-hydroquinoline thus formed, being insoluble in the alkaline layer, separated and was extracted several ~s~so times with a mixture of chloroform and isopropanol.
The extracts were combined and the combined extracts washed wi~h saturated aqueous sodium chloride and then dried. Evaporation of the solvent in vacuo yielded trans-dl-l~methyl-6-oxodecahydroquinoline boiling in the range 105-116C. at 6 torr; yield =
7.7 g. (45%).
Following the above procedure, 29.5 g. of trans-dl-l-n-propyl-6-hydroxydecahydroquinoline were dissolved in 300 ml. of glacial acetic acid to which was added 8 ml. of 18N aqueous sulfuric acid.
55 ml. of a solution of 26.7 g. of chromium trioxide in 23 ml. of 18M sulfuric acid were added in drop-wise fashion. trans-dl-1-n-Propyl-6-oxodecahydro-quinoline formed in the above reaction was isolatedby the above proceduxe; yield = 21.4 g. Still following the above procedure, 49.6 g. of trans-dl-l-benzyl-6-hydroxy-decahydroquinoline were oxidized with chromium trioxide in sulfuric acid to yield trans-dl-1-benzyl-6-oxodecahydroquinoline;
yield = 21.1 g. of a dark oil.
A reaction mixture was prepared from 7.7 g. of trans-dl-1-methyl-6-oxodecahydroquinoline, 36 g~ of the dimethyl acetal of dimethylformamide and 250 ml. of benzene. 3enzene was removed by distillation at atmospheric pressure under nitrogen until about 1/2 the original volume remained (1.25 hours). Sufficient benzene was then added to make up the volume to the original volume and the process was repeated (four times). All of the benzene was - 5 0 6 OB 11~5750 finally removed by evaporation in vacuo and the resulting residue dissolved in 100 g. of dimethyl-formamide dimethylacetal. This solution was heated to refluxing temperature under nitrogen for 20 hours. The reaction mixture was then evaporated in vacuo and a chloroform solution of the residue chromatographed over lS0 g. of nFlorisil" using as the eluant, methylene dichloride containing in-creasing amounts (1-5%) of methanol. Fractions containing similar compounds as shown by TLC were combined. The third substance to come off the column was a yellow solid (wt = 3 g.) The solid was heated with 100 ml. of ether and the resulting solution filtered. Concentration of the filtrate to about 50 ml. yielded 590 mg. of trans-dl-l-methyl-6-oxo-7-dimethylaminomethylenedecahydroquinoline melting at 107-109C.
Analysis: Calculated: C, 70.23; H, 9.97; N, 12.60;
Found: C, 70.17; H, 9.74; N, 12.87.
The above reaction was repeated except that trans-dl-l-n-propyl-6-oxodecahydroquinoline was used as a starting material and the product was chromatographed over Florisil" using chloroform containing increasing quantities of methanol ~1-5%) as the eluant. trans-dl-l-n-Propyl-6-oxo-7-dimethylaminomethylenedecahydroquinoline was ob-tained.
Following the above procedure, trans-dl-1-benzyl-6-oxodecahydroquinoline was reacted with dimethylformamide dimethylacetal to yield trans-" ~ 1 11~575V
x-50~0~
dl-l-benzyl-6-oxo-7-dimethylaminomethylenedecahydro-quinoline melting at 109-111C. after recrystal-lization from an ether-hexane solvent mixture.
Analysis: Calculated: C, 76.47; H, 8.78; N, 9.29;
Found: C, 76.25; H, 8.66; N, 9.36.
The potassium salt of~glycine was prepared by reacting 975 mg. of glycine with 730 mg. of potassium hydroxide in 100 ml. of anhydrous ethanol.
2.~ g. of trans-dl-1-methyl-6-oxo-7-dimethylamino-methylenedecahydroquinoline were added and the resulting mixture heated at reflux temperature under nitrogen for about 3 hours. The reaction mixture was cooled, the volatile constituents removed in vacuo and the residue diluted with ether. The resulting mixture was filtered and the adduct weighed 3.5 g. The glycine adduct was then cyclized, decarboxylated and acetylated by heating with 100 ml. of acetic anhydride at reflux temperature under nitrogen for about 45 minutes. The acetyla-tion mixture was cooled and the volatile constituents removed by evaporation to dryness~ The residue, compri~ing trans-dl-2-acetyl-5-methyl-4,4a,5,6,-7,8,8a,9-octahydro-2H-pyrrolo~3,4-g]quinoline was suspended in methylene dichloride and the suspension filtered to yield 1.7 g. of solid. The methylene ~ichloride filtrate was chromatographed over 150 g.
of "Florisil" using methylene dichloride containing increasing (0-5%) amounts of methanol as the eluant.
Fra~tions shown by TLC to contain the same substance X-5060s were combined, and the combined fractions washed with sodium bicarbonate and saturated aqueous sodium chloride and then dried. Evaporation of the solvent in vacuo yielded a residue which was rechromatographed over 30 g. of Floris~ usin~ chloroform containing 5% methanol as the eluant. Fractions shown by TLC
to contain the same substance were combined to yield 1.72 g. of a viscous orangé oil comprising purified trans-dl-2-acetyl-5-methyl-4,4a,5,6,7,8,8a,9-octa-hydro-2H-pyrrolo[3,4-g~quinoline. The orange oil was dissolved in ether and a solution of 870 mg. of maleic acid in ether added thereto. The maleate salt thus formed melted at 201-203C. after re-crystallization from methanol ether solvent mixture (1:2).
Analysis: Calculated: C, 62.05; H, 6.94; N, 8.04;
Found; C, 61.81; H, 6.82; N, 1.97.
Following the above procedure, trans-dl-2-acetyl-S-n-propyl-4,4a,5,6,7,8,8a,9-octahydro-2~-pyrrolo~3,4-g]quinoline was prepared from trans-dl-2-n-propyl-6-oxo-7-dimethylaminomethylenedeca-hydroquinoline by reaction with the potassium salt of glycine followed by acetic anhydride. The compound was purified by chromatography.
Following the above procedure, trans-dl-l-benzyl-6-oxo-7-dimethylaminomethylenedecahydro-quinoline was reacted with the potassium salt of glycine and acetic anhydride to yield trans-dl-2-acetyl-5-benzyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo[3,4-g3quinoline. This latter derivative was ~l~S7SO
purified by chromatography over Florisil n and then converted to the maleate salt. Trans-dl-2-acetyl-5-benzyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo[3,4-g]quinoline maleate melted at 162-164C. after recrystallization from a methanol-ether solvent mixture.
Analysis: calc.: C, 67.91; H, 6.65; N, 6.60;
Found : C, 67.76; H, 6.40; N, 6.58.
Example B
Preparation of trans-dl-2-Acetyl-5-n-Propyl-4,4a,-5,6,7,8,8a,9-octahydro-2H-pyrrolo[3,4-g]quinoline.
A solution was prepared from 2.5 g. of trans-dl-2-acetyl-5-benzyl-4,4a,5,6,7,8,8a,9-octa-hydro-2H-pyrrolo[3,4-g]quinoline and 200 ml. of methylene dichloride. 4 g. of cyanogenbromide were added and the resulting mixture was stirred at ambient temperature under a nitrogen atmosphere for about 16 hours. Volatile constituents were removed by evaporation in vacuo. A chloroform solution of the residue containing trans-dl-l-acetyl-S-cyano~
4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo[3,4-g]quino-line formed in the above reaction was chromato-graphed over 200 g. of "Florisil~ using chloroform as the eluant. Fractions shown to contain the desired compound were combined and the solvent removed therefrom. Recrystallization of the residue from ether yielded crystalline tran~-dl-2-acetyl-5-cyano-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo-1145~75'0 [3,4-g]quinoline melting at 135-7C. (total yield =
630 mg.) A mixture of 0.6 g. of trans-dl-2-acetyl-5-cyano-4,4a,5,6,7,8,8a,9-octahydro-2H
pyrrolo[3,4-g]quinoline, 50 ml. of glacial acetic acid, 10 ml. of water and 3 g. zinc dust was heated at refluxing temperature under a nitrogen atmosphere for about 7 hours. The reaction mixture was then filtered and the filtrate poured over ice. The aqueous filtrate was then made basic with 14N
aqueous ammonium hydroxide. The aqueous alkaline layer was extracted several times with a mixture of chloroform and isopropanol. The organic extracts were combined and the combined extracts washed with saturated aqueous sodium chloride and then dried.
Evaporation of the solvent in vacuo yielded a residue which was shown to be one-spot material by TLC. The residue was dissolved in 50 ml. of di-methylformamide to which was added 0.~ g. potassium carbonate and 0.4 ml. of n-propyl iodide. This reaction mixture was stirred at ambient temperature under a nitrogen atmosphere for about 16 hours. The reaction mixture was then diluted with water and the diluted mixture extracted with ethyl acetate. The ethyl acetate extract was washed with water and saturated aqueous sodium chloride and then dried.
Evaporation of the solvent in vacuo yielded a residue shown to contain one major spot by TLC of the productO trans-2-acetyl-5-n-propyl-4,4a,5,6,7,-
Also following the above procedure, a mixture of the l-benzyl-6~benzoyloxyhexahydro-2(lH)-quinolinones was prepared by substituting benzyl bromide for methyl iodide.
ll~S7SO`
A solution of 47.3 g. of a mixture of 1-methyl-6-benzoyloxy-3,4,5,6,7,8-hexahydro- 2 (lH) -quinolinone and the corresponding 3,4,4a,5,6,7-hexahydro isomer as obtained above were dissolved in 800 ml. of THF and the solution cooled to about 0C.
20 g. of lithium aluminum hydride were added thereto in portions and the resulting mixture refluxed for four hours under a nitrogen atmosphere. The reaction mixture was cooled and excess lithium aluminum hydride destroyed by the addition of ethyl acetate.
10~ sodium hydroxide was then added and the mixture diluted with water to decompose any organometallics - present. The aqueous mixture was extracted several times with a chloroform-isopropanol solvent mixture.
The organic extracts were combined and the combined extracts washed with saturated aqueous sodium chloride and then dried. Evaporation of the solvent yielded as a residue a mixture of the enamines--l-methyl-6-hydroxy-1,2,3,4,5,6,7,8-octahydroquino-line and 1-methyl-6-hydroxy-1,2,3,4,4a,5,6,7-octahydroqu$nol~ne--formed in the above reaction.
(The lithium aluminum hydride reduction served to remove the benzoyl group at C-6 as a benzyl alcohol moiety, leaving a free hydroxyl in that position of the ring). The above residue, without further purification, was dissolved in about 300 ml. of ether and the ethereal solution saturated with gaseous hydrogen chloride, thus forming the hydro-chloride salt of the enamine mixture. The ether was removed by decantation and the residue dissolved in .
, a mixture of 200 ml. of THF and 50 ml. of methanol.
This solution was cooled in an ice water bath. 12 g. of sodium cyanoborohydride were added with cooling and stirring. After all of the cyano-borohydride had been added, the reaction mixture wasstirred for another 60 minutes and then poured over a mixture of ice and lN aqueous hydrochloric acid.
The acidic aqueous solution was extracted with chloroform and the chloroform extract discarded.
The solution was then made basic with 14N aqueous ammonium hydroxide. Trans-dl-l-methyl-6-hydroxy-decahydroquinoline formed in the above reaction, being insoluble in the alkaline medium, separated and was extracted several times with a chloroform-isopropanol solvent mixture. The combined extracts were washed with saturated aqueous sodium chloride and then dried. Evaporation of the solvent yielded 15 g. of trans-dl-1-methyl-6-hydroxydecahydroquino-line.
Following the above sequence of reactions, a mixtùre of l-n-propyl-6-benzoyloxy-3,4,5,6,7,8-hexahydro-2(1H)-quinolinone and the corresponding 3,4,4a,5,6,7-hexahydro isomer were first reduced with lithium aluminum hydride to yield a mixture of ~4a and ~8 1-n-propyl-6-hydroxyoctahydroquinolines which was converted by treatment with ethereal hydrogen chloride to the enamine hydrochloride.
Reduction of this intermediate enamine hydrochloride with sodium cyanoborohydride yielded trans-dl-1-n-propyl-6-hydroxydecahydroquinoline (56 g. of starting material yielded 30 g. of product). Also following the above proceduxe, l-benzyl-6-benzoyl-oxy-3,4,5,6,7,8-hexahydro-2(lH)-quinolinone in admixture with l-benzyl-6-benzoyloxy-3,4,4a,5,-6,7-h~xahydro-2(lH)-quinolinone was reduced with lithium aluminum hydride to yield the corresponding l-benzyl-6-hydroxy-1,2,3,4,5,6,7,8-octahydroquino-line and l-benzyl-6-hydroxy-1,2,3,4,4a,5,6,7-octahydroquinoline as a mixture, treatment of which with ethereal hydrogen hydrochloride yielded the enamine salt. Reduction of the enamine salt with sodium cyanoborohydride gave 1-benzyl-6-hydroxydeca-hydroquinoline (65 g. of starting mixture yielded 49.6 g. of final product).
Fifteen grams of trans-dl-l-methyl-6-hydroxydecahydroquinoline were dissolved in 250 ml.
of 6N aqueous sulfuric acid. The solution was cooled in an ice-water bath. A solution of 9 g. of chromium trioxide in 60 ml. of 6N aqueous sulfuric acid were added thereto with stirring in dropwise fashion over a 10-minute period. The cooling bath was removed and the reaction mixture stirred for an additional 60 minutes at ambient temperature. The excess oxidizing agent was decomposed by adding isopropanol to the reaction mixture. The reaction mixture was next poured over ice and the acidic aqueous olution made basic with 14N aqueous ammonium hydroxide. trans-dl-l-Methyl-6-oxodeca-hydroquinoline thus formed, being insoluble in the alkaline layer, separated and was extracted several ~s~so times with a mixture of chloroform and isopropanol.
The extracts were combined and the combined extracts washed wi~h saturated aqueous sodium chloride and then dried. Evaporation of the solvent in vacuo yielded trans-dl-l~methyl-6-oxodecahydroquinoline boiling in the range 105-116C. at 6 torr; yield =
7.7 g. (45%).
Following the above procedure, 29.5 g. of trans-dl-l-n-propyl-6-hydroxydecahydroquinoline were dissolved in 300 ml. of glacial acetic acid to which was added 8 ml. of 18N aqueous sulfuric acid.
55 ml. of a solution of 26.7 g. of chromium trioxide in 23 ml. of 18M sulfuric acid were added in drop-wise fashion. trans-dl-1-n-Propyl-6-oxodecahydro-quinoline formed in the above reaction was isolatedby the above proceduxe; yield = 21.4 g. Still following the above procedure, 49.6 g. of trans-dl-l-benzyl-6-hydroxy-decahydroquinoline were oxidized with chromium trioxide in sulfuric acid to yield trans-dl-1-benzyl-6-oxodecahydroquinoline;
yield = 21.1 g. of a dark oil.
A reaction mixture was prepared from 7.7 g. of trans-dl-1-methyl-6-oxodecahydroquinoline, 36 g~ of the dimethyl acetal of dimethylformamide and 250 ml. of benzene. 3enzene was removed by distillation at atmospheric pressure under nitrogen until about 1/2 the original volume remained (1.25 hours). Sufficient benzene was then added to make up the volume to the original volume and the process was repeated (four times). All of the benzene was - 5 0 6 OB 11~5750 finally removed by evaporation in vacuo and the resulting residue dissolved in 100 g. of dimethyl-formamide dimethylacetal. This solution was heated to refluxing temperature under nitrogen for 20 hours. The reaction mixture was then evaporated in vacuo and a chloroform solution of the residue chromatographed over lS0 g. of nFlorisil" using as the eluant, methylene dichloride containing in-creasing amounts (1-5%) of methanol. Fractions containing similar compounds as shown by TLC were combined. The third substance to come off the column was a yellow solid (wt = 3 g.) The solid was heated with 100 ml. of ether and the resulting solution filtered. Concentration of the filtrate to about 50 ml. yielded 590 mg. of trans-dl-l-methyl-6-oxo-7-dimethylaminomethylenedecahydroquinoline melting at 107-109C.
Analysis: Calculated: C, 70.23; H, 9.97; N, 12.60;
Found: C, 70.17; H, 9.74; N, 12.87.
The above reaction was repeated except that trans-dl-l-n-propyl-6-oxodecahydroquinoline was used as a starting material and the product was chromatographed over Florisil" using chloroform containing increasing quantities of methanol ~1-5%) as the eluant. trans-dl-l-n-Propyl-6-oxo-7-dimethylaminomethylenedecahydroquinoline was ob-tained.
Following the above procedure, trans-dl-1-benzyl-6-oxodecahydroquinoline was reacted with dimethylformamide dimethylacetal to yield trans-" ~ 1 11~575V
x-50~0~
dl-l-benzyl-6-oxo-7-dimethylaminomethylenedecahydro-quinoline melting at 109-111C. after recrystal-lization from an ether-hexane solvent mixture.
Analysis: Calculated: C, 76.47; H, 8.78; N, 9.29;
Found: C, 76.25; H, 8.66; N, 9.36.
The potassium salt of~glycine was prepared by reacting 975 mg. of glycine with 730 mg. of potassium hydroxide in 100 ml. of anhydrous ethanol.
2.~ g. of trans-dl-1-methyl-6-oxo-7-dimethylamino-methylenedecahydroquinoline were added and the resulting mixture heated at reflux temperature under nitrogen for about 3 hours. The reaction mixture was cooled, the volatile constituents removed in vacuo and the residue diluted with ether. The resulting mixture was filtered and the adduct weighed 3.5 g. The glycine adduct was then cyclized, decarboxylated and acetylated by heating with 100 ml. of acetic anhydride at reflux temperature under nitrogen for about 45 minutes. The acetyla-tion mixture was cooled and the volatile constituents removed by evaporation to dryness~ The residue, compri~ing trans-dl-2-acetyl-5-methyl-4,4a,5,6,-7,8,8a,9-octahydro-2H-pyrrolo~3,4-g]quinoline was suspended in methylene dichloride and the suspension filtered to yield 1.7 g. of solid. The methylene ~ichloride filtrate was chromatographed over 150 g.
of "Florisil" using methylene dichloride containing increasing (0-5%) amounts of methanol as the eluant.
Fra~tions shown by TLC to contain the same substance X-5060s were combined, and the combined fractions washed with sodium bicarbonate and saturated aqueous sodium chloride and then dried. Evaporation of the solvent in vacuo yielded a residue which was rechromatographed over 30 g. of Floris~ usin~ chloroform containing 5% methanol as the eluant. Fractions shown by TLC
to contain the same substance were combined to yield 1.72 g. of a viscous orangé oil comprising purified trans-dl-2-acetyl-5-methyl-4,4a,5,6,7,8,8a,9-octa-hydro-2H-pyrrolo[3,4-g~quinoline. The orange oil was dissolved in ether and a solution of 870 mg. of maleic acid in ether added thereto. The maleate salt thus formed melted at 201-203C. after re-crystallization from methanol ether solvent mixture (1:2).
Analysis: Calculated: C, 62.05; H, 6.94; N, 8.04;
Found; C, 61.81; H, 6.82; N, 1.97.
Following the above procedure, trans-dl-2-acetyl-S-n-propyl-4,4a,5,6,7,8,8a,9-octahydro-2~-pyrrolo~3,4-g]quinoline was prepared from trans-dl-2-n-propyl-6-oxo-7-dimethylaminomethylenedeca-hydroquinoline by reaction with the potassium salt of glycine followed by acetic anhydride. The compound was purified by chromatography.
Following the above procedure, trans-dl-l-benzyl-6-oxo-7-dimethylaminomethylenedecahydro-quinoline was reacted with the potassium salt of glycine and acetic anhydride to yield trans-dl-2-acetyl-5-benzyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo[3,4-g3quinoline. This latter derivative was ~l~S7SO
purified by chromatography over Florisil n and then converted to the maleate salt. Trans-dl-2-acetyl-5-benzyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo[3,4-g]quinoline maleate melted at 162-164C. after recrystallization from a methanol-ether solvent mixture.
Analysis: calc.: C, 67.91; H, 6.65; N, 6.60;
Found : C, 67.76; H, 6.40; N, 6.58.
Example B
Preparation of trans-dl-2-Acetyl-5-n-Propyl-4,4a,-5,6,7,8,8a,9-octahydro-2H-pyrrolo[3,4-g]quinoline.
A solution was prepared from 2.5 g. of trans-dl-2-acetyl-5-benzyl-4,4a,5,6,7,8,8a,9-octa-hydro-2H-pyrrolo[3,4-g]quinoline and 200 ml. of methylene dichloride. 4 g. of cyanogenbromide were added and the resulting mixture was stirred at ambient temperature under a nitrogen atmosphere for about 16 hours. Volatile constituents were removed by evaporation in vacuo. A chloroform solution of the residue containing trans-dl-l-acetyl-S-cyano~
4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo[3,4-g]quino-line formed in the above reaction was chromato-graphed over 200 g. of "Florisil~ using chloroform as the eluant. Fractions shown to contain the desired compound were combined and the solvent removed therefrom. Recrystallization of the residue from ether yielded crystalline tran~-dl-2-acetyl-5-cyano-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo-1145~75'0 [3,4-g]quinoline melting at 135-7C. (total yield =
630 mg.) A mixture of 0.6 g. of trans-dl-2-acetyl-5-cyano-4,4a,5,6,7,8,8a,9-octahydro-2H
pyrrolo[3,4-g]quinoline, 50 ml. of glacial acetic acid, 10 ml. of water and 3 g. zinc dust was heated at refluxing temperature under a nitrogen atmosphere for about 7 hours. The reaction mixture was then filtered and the filtrate poured over ice. The aqueous filtrate was then made basic with 14N
aqueous ammonium hydroxide. The aqueous alkaline layer was extracted several times with a mixture of chloroform and isopropanol. The organic extracts were combined and the combined extracts washed with saturated aqueous sodium chloride and then dried.
Evaporation of the solvent in vacuo yielded a residue which was shown to be one-spot material by TLC. The residue was dissolved in 50 ml. of di-methylformamide to which was added 0.~ g. potassium carbonate and 0.4 ml. of n-propyl iodide. This reaction mixture was stirred at ambient temperature under a nitrogen atmosphere for about 16 hours. The reaction mixture was then diluted with water and the diluted mixture extracted with ethyl acetate. The ethyl acetate extract was washed with water and saturated aqueous sodium chloride and then dried.
Evaporation of the solvent in vacuo yielded a residue shown to contain one major spot by TLC of the productO trans-2-acetyl-5-n-propyl-4,4a,5,6,7,-
8,8a,9-octahydro-2H-pyrrolol3,4-glquinoline.
1145'750 Exam~le C
Preparation of trans-dl-2-Acetyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo~3,4-g]quinoline.
3.5 Grams of trans-dl-2-acetyl-5-benzyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo[3,4-g]quino-line were dissolved in 196 ml. of ethanol to which solution was added O.S g. of a 5% palladium-on-carbon catalyst. The mixture was hydrogenated in an Adams machine at room temperature at an initial hydrogen pressure of 4.13 x 106 dynes/cm.2. After 2 hours, lO0~ of the theoretical amount of hydrogen had been absorbed. The hydrogenation mixture was removed from the machine and the catalyst separated lS by filtration. TLC indicated that there were two major spots, one being starting material. The filtrate was concentrated in vacuo to yield crys-talline material. Concentration of the filtrate yielded a further batch of crystalline material.
These two batches were combined, dissolved in water and the aqueous solution made basic with 14N aqueous ammonium hydroxide. The alkaline layer was ex-tracted several times with a mixture of chloroform and isopropanol. The organic extracts were combined and the combined extracts were washed with saturated aqueouC sodium chloride and dried. Evaporation of ~he solvent yielded a residue comprising trans-dl-2-acetyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo-13,4-g]~uinoline formed in the above hydrogenation.
The residue was washed with hexane. It melted at 1145750 ` .
89-91C. The maleate salt was prepared by dis-solving the residue in ether and adding an excess of maleic acid in ether. The maleate salt was re-crystallized from a mixture of methanol and ether S and melted at 150-1C.
Example D
Preparation of trans-dl-4,4a,5,6,7,8,8a,9-Octa-hydro-2H-pyrrolol3,4-glquinoline.
Three-tenths grams of trans-dl-2-acetyl-4,4a,S,6,7,8,8a,9-octahydro-2H-pyrrolo[3,4-g]-quinoline were dissolved in lS ml. methanol to which was added 2 ml. of 2N aqueous sodium hydroxide. The hydrolysis mixture was stirred at ambient tempera-lS ture under nitrogen for 3/4 hour. The reaction mixture was then diluted with water and the alkaline layer extracted with a mixture of chloroform and isopropanol. The organic extract was separated, washed with saturated aqueous sodium chloride and then dried. Evaporation of the solvent yielded a residue showinq a sinqle spot by TLC. The residue was dissolved in ether and an excess of an ethereal solution of maleic acid added thereto. The re-sulting gummy precipitate was separated, dissolved in methanol, and the methanol solution diluted with ether to yield crystalline material. tranq-dl-4,4a,5,6,7,8,8a,9-Octahydro-2H-pyrrolo[3,4-g]quino-line maleate thus prepared melted at 190C. with decomposit~on.
.
~: . . ~ . . . .
' : ' . . :
- ~ ~
X-50~0B
Example E
Preparation of l-n-Propyl-6-benzoyloxy-3,4,5,6,7,8-hexahydro-2(lH)-quinolinone and l-n-Propyl-6-benzoyloxy-3,4,4a,5,6,7-hexahydro-2(lH)-quinolinone A reaction mixture was prepared containing 4.4 g. of 4-benzoyloxycyclohexanone [prepared by the procedure of E. R. H. Jones and F. Sondheimer, J.
Chem. Soc., 615 (1949)], 2.5 ml. of n-propylamine and 100 ml. toluene. The mixture was heated to reflux temperature in a nitrogen atmosphere using a Dean Stark water trap for about 2 hours. The reaction mixture was then heated to refluxing temperature for an additional 2 hours in the presence of a molecular sieve to remove water. The reaction mixture was then cooled and the solvent removed by evaporation in vacuo. 4 ml. of methyl acrylate and 100 ml. of dioxane were added to the residue which was then refluxed overnight under a nitrogen atmosphere. The reaction mixture was again cooled and the volatile constituents removed by evaporation in va¢uo. Chromatography of an ethereal solution of the resulting residue over 200 g. of "Florisil" using ether as an eluant yielded a mixture of 1-n-propyl-6-henzoyloxy-3,4,5,6,7,8-hexahydro-2tlH)-quinolinone and l-n-propyl-6-benzoyloxy-3,4,4a,5,6,7-hexahydro-2(1H)-quinolinone: yield =
2.15 g.
X - 5 0 6 0 B :1145750 Example F
Preparation of trans-dl-2-Acetyl-5-n-propyl-7-ethoxycarbonyl-4,4a,5,6,7,8,8a,9-octahydropyrrolo-[3,4-g]quinoline A mixture of 10 ml. of n-propyl amine and 400 ml. of toluene were cooled in an ice-water bath.
A solution of 16.5 g. of ethyl a-(bromomethyl)-acrylate in 50 ml. of toluene was added thereto in dropwise fashion. The resulting mixture was stirred with cooling for about 25 minutes. Next, a solution of 11 g. of 4-benzoyloxycyclohexanone in 75 ml. of toluene was added in dropwise fashion. This new mixture was heated under a nitrogen atmosphere to refluxing temperature for about 23 hours. The reflux condenser was equipped with a Soxhlet extractor containing a 5A sieve to remove water.
Next the rea~tion mixture was cooled and the cooled mixture filtered. Evaporation of the filtrate yielded a residue comprising a mixture of l-n-propyl-3-ethoxycarbonyl-6-benzoyloxy-1,2,3,4,5,-6,7,8-octahydroquinoline and 1-n-propyl-3-ethoxy-carbonyl-6-benzoyloxy-1,2,3,4,4a,5,~,7-octahydro-quinoline. The residue was dissolved in an ether-chloroform solvent mixture and the resultingsolution saturated with gaseous hydrogen chloride while maintaining the temperatuxe in the range 0-5C. The solve~t was decanted from the crys-talline hydrochloride salts thus formed. The salts 3~ were dissolved in 100 ml. of methanol. 300 ml. of , 11~5750 THF were added and the resulting solution cooled in an ice-water bath. 15 g. o sodium cyanoborohydride were added in portions to the stirred and cooled reaction mixture. After the addition had been completed, the reaction mixture was stirred for another 1.25 hours after which time it was diluted with aqueous sodium bicaxbonate. The aqueous alkaline mixture was extracted several times with ethyl acetate. The ethyl acetate extracts were combined and the combined extracts washed with saturated aqueous sodium chloride solution and then dried. Evaporation of the solvent yielded trans-dl-l-n-propyl-3-ethoxycarbonyl-6-benzoyloxydeca-hydroquinoline. The compound was dissolved in a mixture of 400 ml. of methanol and 100 ml. of 2N
aqueous sodium hydroxide. This mixture was stirred at ambient temperature under a nitrogen atmosphere for 64 hours after which time the volatile con-stituents were removed by evaporation in vacuo. The re~ulting residue was suspended in 800 ml. of ethanol and 15 ml. of 12N aqueous hydrochloric acid.
The esterification mixture was heated to refluxing temperature and about 300 ml. of solvent removed by distillation. 300 ml. of additional ethanol were added and the reaction mix~ure heated to refluxing temperature for 26 hours in an apparatus equipped with a Soxhlet trap containing a 3A sieve. The reaction mixture was cooled, diluted with aqueous sodium bicarbonate and the alkaline mixture ex-tracted several times with chloroform. The chloro-11~5750 form extracts were combined and the combined ex-tracts washed with saturated aqueous sodium chloride and then dried. Evaporation of the chloroform yielded 10.3 g. of a residue which was purifled by chromatography over 150 g. of "Florisil~ using chloroform containing increasing (2-10%) of methanol as the eluant. Trans-dl-l-n-propyl-3-ethoxycar-bonyl-6-hydroxydecahydroquinoline formed in the above reaction was obtained from the eluate frac-tions as a purified product.
A solution was prepared from 8.8 g. oftrans-dl-l-n-propyl-3-ethoxycarbonyl-6-hydroxydeca-hydroquinoline and 400 ml. of methylene dichloride.
41 g. of sodium acetate were added. Next, 10.8 g.
o pyridine hydrochloride:chromium trioxide were added and the resulting mixture stirred for about 22 hours. The reaction mixture was filtered and the iltrate concentrated in vacuo. The resulting concentrate was dissolved in chloroform and the chloroform solution chromatographed over 150 g. of "Florisill~using chloroform containing increasing amounts (1-2%) of methanol as the eluant. Fractions shown by thin-layer chromatography to contain tran3-dl-l-n-propyl-3-ethoxycarbonyl-6-oxodeca-hydroquinoline formed in the above reaction werecombined and the solvent removed from the combined extracts to yield 3.48 g. of the 6-oxo compound as a residue. The 6-oxo compound was dissolved in 100 ml. of toluene containing an added 25 ml. of the dimethylacetal of dimethylformamide. The resulting ~1145750 ~-50~0~
mixture was heated to refluxing temperature under a nitrogen atmosphere for 44 hours and was then allowed to remain at room temperature for an additional 4 days. Volatile constituents were S removed by evaporation in vacuo and the residue, comprising trans-dl-l-n-propyl-3-ethoxycarbonyl-6-oxo-7-(dimethylaminomethylene)decahydroquinoline formed in the above reaction, was purified ~y chromatographing a chloroform solution of the compound ov~er '~Florlsil~ using chloroform containing increasing amounts (2-5%) of methanol as the eluant.
Fractions shown by TLC to contain the desired 7-dimethylaminomethylene compound were combined and the solvent evaporated therefrom in vacuo.
The potassium salt of glycine was prepared by reacting 280 mg. of potassium hydroxide with 370 mg. of glycine in 50 ml. of anhydrous ethanol.
1.3 g. of trans-dl-l-n-propyl-3-ethoxycarbonyl-6-oxo-7-(dimethylaminomethylene)decahydroguinoline were added and the resulting mixture heated under a nitrogen atmosphere to reflux temperature for about 3 hours. The reaction mixture was cooled and the volatile constituents removed by evaporation in vacuo. 50 ml. of acetic anhydride were added to this residue and the resulting mixture heated to reflux temperature under a nitrogen atmosphere for about 45 minutes thus cyclizing, decarboxylating and acetylating all in one step. Again/ the reaction mixture was cooled and the volatile constituents removed by evaporation. In this instance, the X-5060s residue was next diluted with aqueous sodium bi-carbonate and the resulting alkaline aqueous layer extracted with chloroform. The chloroform extract was separated and the separated extract washed with saturated aqueous sodium becarbonate and then dried.
~vaporation of the chloroform yielded a residue which was chromatographed over 35 g. of "Florisil"
using chloroform containing increasing amounts (0-1%) of methanol as the eluant. Fractions shown by TLC to contain the desired trans-dl-2-acetyl-5-n-propyl-7-ethoxycarbonyl-4,4a,5,6,7,8,8a,9-octahydropyrrolo~3,4-g]quinoline formed in the above reaction were combined. The solvent was removed from the combined fractions by evaporation and the resulting residue was dissolved in ether. This ether solution was treated with an excess of maleic acid, also in ether. The resulting precipitate comprising the maleate salt of trans-dl-2-acetyl-5-n-propyl-7-ethoxycarbonyl-4,4a,5,6,7,8,8a,9-octahydropyrrolo[3,4-glquinoline melted at 179-180C. after crystallization from a methanol-ether solvent mixture; yield = 280 mg.
Analysis Calculated: C, 61.59; H, 7.19; N, 6.25;
Found: C, 61.32; H, 6.37; N, 6.53.
690 mg. of trans-dl-2-acetyl-5-n-propyl-7-ethoxycarbonyl-4,4a,5,6,7,8,8a,9-octahydropyrrolo-t3,4-g]quinoline maleate were dissolved in ethanol and this solution added to a solution containing an excess of sodium ethylate in ethanol. The reaction X-50~0s mixture was stirred for 1~2 hour after which time it was diluted with water and the aqueous mixture extracted with chloroform. The chloroform extract was separated, washed with saturated aqueous sodium chloride and then dried. Evaporation of the chloro-form yielded trans-dl-5-n-propyl-7-ethoxycaxbonyl-4,4a,5,6,7,8,8a,9-octahydropyrrolo[3,4-g]quinoline formed in the above reaction. The free base melted at 163-4C. after recrystallization from ethanol.
Analysis calculated: C, 70.31; H, 9.02; N, 9.65 Found: C, 70.22; H, 8.91; N, 9.94.
About 1/2 gram of trans-dl-5-n-propyl-7-ethoxycarbonyl-4,4a,5,6,7,8,8a,9-octahydropyrrolo-[3,4-g]quinoline were dissolved in 75 ml. of tetra-hydrofuran. 1 g. of lithium aluminumhydride was added thereto in small portions. After all of the lithium aluminumhydride had been added, the reaction mixture was stirred for another 2.25 hours after which time the excess lithium aluminumhydride was decomposed by the addition of ethyl acetate and any organometallic salts present decomposed by the addition of 10% aqueous sodium hydroxide. The resulting mixture was diluted with water and the aqueous layer extracted several times with chloro-form. The chloroform extracts were separated and combined and the combined extracts washed with saturated aqueous sodium chloride and then dried.
Evaporation of the solvent yielded as a residue, trans-dl-5-n-propyl-7-hydroxymethyl-4,4a,5,6,7,8,-8a,9-octahydropyrrolo[3,4-g]quinoline, which melted 11~5750 X- 5 0 ~; O B
at 178-180C. after recrystallization from a ethyl ace~ate/ether solvent mixture.
Analysis calculated: C, 72.54; H, 9.74; N, 11.28 Found: C, 72.30; H, 9.73; N, 11.05.
About 0.4 g. cf trans-dl-5-n-propyl-7-hydroxymethyl-4,4a,5,6,7,8,8a,9-octahydropyrrolo-[3,4-g]quinoline were dissolved in 25 ml. of pyridine.
0.5 ml. of methanesulfonyl chloride were added and the resulting mixture stirred for 0.75 hours at room temperature. The reaction mixture was dilu~ed with water and sufficient 14N aqueous a nium hydroxide added to make the reaction mix~ure basic. The a~US mixture was extracted several times with ethyl acetate. The ethyl acetate extracts were combined and the combined extracts washed first with water and then with saturated aqueous ammonium chloride and were then dried. The residue obtained by evaporation of the æolvent was chromatographed over 30 g. of "Plorisil'~' and the chromatogram ~lq~
with chloroform containing increasing quantities ~2-4%) of methanol as the eluant. Fractions shown by thin-layer chromatography to contain the desired methanesulfonyl ester were combined and the solvent re ved ~herefrom ln _acuo. The resulting residue, tran-~-dl-5-n-propyl-7-mesyloxymethyl-4,4a,5,6,7,-8,8a,9-octahydropyrrolo[3,4-g]quinoline was crys-tallized from ethanol; m.p. = 150C. with decomposi-tion.
X-5()60B
FINAL PRODUCTS
Example 1 Preparation of trans-dl-5-Methyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo[3,4-g]ql~inoline from the Corresponding 2-Acetyl Compound.
One and two-tenths grams of trans-dl-2-acetyl-5-methyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo[3, 4-g] quinoline maleate were suspended in 100 ml. of methanol and 10 ml. of 2N aqueous sodium hydroxide were added. The resulting mixture was stirred at room temperature under a nitrogen atmosphere for about 35 minutes and was then diluted with dilute aqueous sodium hydroxide. The resulting alkaline solution was extracted several ~imes with chloroform. The chloroform extracts were combined and the combined extracts washed with saturated aqueous sodium chloride and dried. Evaporatisn of the chloroform yielded 400 ml. of crystalline material melting at 190-6C. with decomposition. A
chloroform solution of the material was then chromatographed o~er 30 g. of "Floris~" using chloro-form containing increasing amounts (2-5%~ of methanol as the eluant. The second major component to be eluted from the column consisted of trans-dl-S-methyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo-13,4-g]quinoline. Fractions containing this compound were combined and the solvent removed from the combined fractions by evaporation. Recrystal-lization of the residue from ether yielded trans-i~s~so ,~-5060B
dl-5-methyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo-t3,4-g]quinoline melting at 200-222C. with decom-position (80 mg.).
Analysis: calc.: C, 75.74 H, 9.53; N, 14.72;
Found : C, 75,8B H, 9.28; N, 14.55.
Following the above procedure, trans-dl-2-acetyl-5-n-propyl-4,4a,5,6,7,8,8a,9-octa-hydro-2H-pyrrolo[3,4-g}quinoline (4.8 g) was hydrolyzed with dilute aqueous sodium hydroxide.
c trans-dl-5-n-Propyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo[3,4-g]quinoline thus prepared was purified by ch~omotography over UFlorisil''using chloroform containing increasing amounts (2-10%) methanol as the eluant. Fractions shown to contain the desired product by TLC were combined and the solvent evaporated therefrom. Recrystallization of the residue from a methanol-ether solvent mixture yielded 245 mg. crystalline trans-dl-5-n-propyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo[3,4-g]quino-Zo line melting at 169-171C. with decomposition; nmr peaks at 52, 384 and 510 cps. (in CDC13).
Analysis: calc.: C, 64.65; H, 7.84; N, 8.38;
~ound : C, 64.40; H, 7.62; N, 8.12.
Example 2 Preparation of trans-dl-5-n-Propyl-4,4a,5,6,7,8,-8a,9-octahydro-2H-pyrrolo[3,4-g]quinoline.
The product trans-dl-2-acetyl-5-n-propyl-4,4a,5,6,7,8,Ba,9-octahydro-2H-pyrrolo[3,4-g]quinoline (from Example B~ was dissolved in 20 ml. of methanol 3o . . ' .
.
.
to which was added 3 ml. of ZN aqueous sodium hydroxide. This reaction mixture was stirred at ambient temperature under a nitrogen atmosphere for 65 min. The reaction mixture was diluted with water and the diluted mixture extracted several times with chloroform. The chloroform extracts were combined and the combined extracts washed with saturated aqueous sodium chloride and then dried. Evaporation of the chloroform yielded a residue which was shown to contain one major spot by TLC. An ether solution of the xesidue, comprising trans-dl-5-n-propyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo[3,4-g]quino-line formed in the above reaction, was treated with an excess of maleic acid in ether solution, thus forming the maleate salt of the base. The maleate salt was separated by filtration and recrystallized from an ether-methanol solvent mixture. trans-dl-5-n-Propyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo-~3,4-g]quinoline maleate thus prepared melted 168-170C, with decomposition; yield - 215 mg.
Example 3 The mesylate ester (prepared in Example F) can be reacted with the sodium salt of methyl-mercaptan to yield trans-dl-5-n-propyl-7-methyl-mercaptomethyl-4,4a,5,6,7,8,8a,9-octahydropyrrolo-13,4-g]quinoline.
As evidence of the utility of the compounds of formula I, it has been found that they affect turning behavior in rats in a test procedure , . ~ - - ~ .
designed to uncover compounds useful for the treatment of Parkinsonism utilizing 6-hydroxy-dopamine-lesioned rats. In this test, nigro-neostriatal-lesioned rats are employed, as prepared by the procedure of Ung~erstedt and Arbuthnott, ~rain Res, 24, 485 ~1970). A compound having dopamine agonist activity causes the rats to turn in circles contralateral to the side of the lesion. After a latency period, which varies from compound to compound, the number of turns is ~ounted over a 15-minute period.
Results obtained from testing representa-tive compounds of formula I in the rat turning test are set forth in Table 1 below. The compounds were dissolved in water and the aqueous solution injected into the rat by the intraperitoneal route at a dose level of 1 mg/kg. In the table, column 1 gives the name of the compound, column 2, percent of test animals exhibiting turning behavior, and column 3, avexage number of turns observed in first 15 minutes after end of latency period.
q) O
a ~1 0 ~ C h o D;-r~-r~ ~ O
~ ~ ~ _~
O ~ ~
~ E~ m ~P ~
~1 _~ ~ Q) 1--.a E~ U~ O
O
~a I ~ ~1 ` ~
~ _~ I O c Q, O 1~ rl C~ O ~ ~
~ . ~ o ~
U C ~ I
I 0~ I ~1 O U~ o I, ~ I (a a~
'O ~ U-~
~ I 1~ _1 1 0--~
Z ~ C~ C I ~
h , , The compounds of formula I are also useful as prolactin inhibitors and as such they can be employed in the treatment of inappropriate lactation such as postpartum lactation and galac-torrhea. As evidence of their utility in thetreatment of diseases such as those in which it is desirable to reduce the prolactin level, the com-pounds of formula I have been shown to inhibit prolactin according to the following procedure.
Adult male rats of the Spraque-Dawley strain weighing about 200 g. were housed in an air-conditioned room with controlled lighting (lights on 6 a.m. - 8 p.m.)-and fed lab chow and water ad libitum. Each rat received an intra-peritoneal injection of 2.0 mg. of reserpine in aqueous ~uspension 18 hours before administration of the test drug. The purpose of the reserpine was to keep prolactin levels uniformly elevated. The compounds under test were disQolved in 10 percent ethanol, and were injected intraperitoneally at doses of 0.5 and 5 mg/kg. Each compound was ad-ministered at each dose level to a group of 10 rats, and a control group of 10 intact males received an equivalent amount of 10 percent ethanol. One hour after treatment, all rats were killed by decapita-tion, and 150 ~1 aliquots of serum were assayed for prolactin.
The difference between the prolactin level of the treated rats and prolactin level of the control rat~, divided by the prolactin level of the control rats gives the percent inhibition of prolactin secretion attributable to the compounds of formula I. These inhibition percentages are given in Table 2 below. In the table, column 1 gives the name of the compound; and columns 2 and 3 ! the percent prolactin inhibition at the 0.5 and 5 mg/kg dose levels.
,..
1~5750 .
o ~:
S ~ ~
a ~ Ll o ~ ~ a~ cn O U~
.,~
C) ~ .Y
O ~ I
I
~ D.
a~ ~ In _~ C Q
~ U
E~
P.
0, O O
' ~ `
l O ~ `~ _ o :~ O S Q~
O ~ ~ C ~: ~1 C
l~ J- rl ~ S-rl O C O O ~:~ O
C.~ I I C I
~ 0~ Ul O-r~
q~
O
~ 00 a~ I ' ~ I ~
~ U~ tD I ~n co I
:Z
. i~45750 In using the compounds of formula I
to inhibit prolactin secretion or to treat Parkinson's syndrome or for other pharmacologic action, a com-pound according to formula I above in which R2 is S Cl-C3 alkyl or allyl and Rl is H or Cl-C3 alkyl, or a salt thereof with a pharmaceutically-acceptable acid, is administered to a subject suffering from Parkin-sonism or in need of having his prolactin level reduced in an effective amount to treat Parkinsonism or to reduce prolactin. Oral administration is preferred. If parenteral administration is used, the injection is preferably by the subcutaneous route using an appropriate pharmaceutical formulation.
Other modes of parenteral administration such as intraperitoneal, intramuscular, or intra~enous routes are equally effective. In particular, wi~h intra-venous or intramuscular administration, a water soluble pharmaceutically-acceptable salt is employed.
For oral administration, the compound either as the free base or in the form of a ~alt thereof can also be mixed w$th standard pharmaceutical excipients and loaded into empty telescoping gelatin capsules or pressed into tablets. For oral administration, the compound either as the free base or in the form of a salt thereof, can also be mix~d with standard pharmaceutical excipients and loaded into empty telescoping gelatin capsules or pressed into tablets.
~he oral dosage range is from about 0.01 to 10 mg. to 10 mg./kg. of mammalian weight and the parenteral dose range from about 0.0025 to 2.5 mg./kg. Intra-` 114S7SO
peritoneal dosages of 10-30 mg./kg. of trans-dl-5-n-propyl-4,4a,5,6,7,8,8a,9-octahydro-pyrrolo-13,4-g]-quinoline dihydrochloride resulted in no - deaths, but dosages of 100-300 mg./kg. were fatal, indicating an LD50 in the range 30-100 mg./kg.
1145'750 Exam~le C
Preparation of trans-dl-2-Acetyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo~3,4-g]quinoline.
3.5 Grams of trans-dl-2-acetyl-5-benzyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo[3,4-g]quino-line were dissolved in 196 ml. of ethanol to which solution was added O.S g. of a 5% palladium-on-carbon catalyst. The mixture was hydrogenated in an Adams machine at room temperature at an initial hydrogen pressure of 4.13 x 106 dynes/cm.2. After 2 hours, lO0~ of the theoretical amount of hydrogen had been absorbed. The hydrogenation mixture was removed from the machine and the catalyst separated lS by filtration. TLC indicated that there were two major spots, one being starting material. The filtrate was concentrated in vacuo to yield crys-talline material. Concentration of the filtrate yielded a further batch of crystalline material.
These two batches were combined, dissolved in water and the aqueous solution made basic with 14N aqueous ammonium hydroxide. The alkaline layer was ex-tracted several times with a mixture of chloroform and isopropanol. The organic extracts were combined and the combined extracts were washed with saturated aqueouC sodium chloride and dried. Evaporation of ~he solvent yielded a residue comprising trans-dl-2-acetyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo-13,4-g]~uinoline formed in the above hydrogenation.
The residue was washed with hexane. It melted at 1145750 ` .
89-91C. The maleate salt was prepared by dis-solving the residue in ether and adding an excess of maleic acid in ether. The maleate salt was re-crystallized from a mixture of methanol and ether S and melted at 150-1C.
Example D
Preparation of trans-dl-4,4a,5,6,7,8,8a,9-Octa-hydro-2H-pyrrolol3,4-glquinoline.
Three-tenths grams of trans-dl-2-acetyl-4,4a,S,6,7,8,8a,9-octahydro-2H-pyrrolo[3,4-g]-quinoline were dissolved in lS ml. methanol to which was added 2 ml. of 2N aqueous sodium hydroxide. The hydrolysis mixture was stirred at ambient tempera-lS ture under nitrogen for 3/4 hour. The reaction mixture was then diluted with water and the alkaline layer extracted with a mixture of chloroform and isopropanol. The organic extract was separated, washed with saturated aqueous sodium chloride and then dried. Evaporation of the solvent yielded a residue showinq a sinqle spot by TLC. The residue was dissolved in ether and an excess of an ethereal solution of maleic acid added thereto. The re-sulting gummy precipitate was separated, dissolved in methanol, and the methanol solution diluted with ether to yield crystalline material. tranq-dl-4,4a,5,6,7,8,8a,9-Octahydro-2H-pyrrolo[3,4-g]quino-line maleate thus prepared melted at 190C. with decomposit~on.
.
~: . . ~ . . . .
' : ' . . :
- ~ ~
X-50~0B
Example E
Preparation of l-n-Propyl-6-benzoyloxy-3,4,5,6,7,8-hexahydro-2(lH)-quinolinone and l-n-Propyl-6-benzoyloxy-3,4,4a,5,6,7-hexahydro-2(lH)-quinolinone A reaction mixture was prepared containing 4.4 g. of 4-benzoyloxycyclohexanone [prepared by the procedure of E. R. H. Jones and F. Sondheimer, J.
Chem. Soc., 615 (1949)], 2.5 ml. of n-propylamine and 100 ml. toluene. The mixture was heated to reflux temperature in a nitrogen atmosphere using a Dean Stark water trap for about 2 hours. The reaction mixture was then heated to refluxing temperature for an additional 2 hours in the presence of a molecular sieve to remove water. The reaction mixture was then cooled and the solvent removed by evaporation in vacuo. 4 ml. of methyl acrylate and 100 ml. of dioxane were added to the residue which was then refluxed overnight under a nitrogen atmosphere. The reaction mixture was again cooled and the volatile constituents removed by evaporation in va¢uo. Chromatography of an ethereal solution of the resulting residue over 200 g. of "Florisil" using ether as an eluant yielded a mixture of 1-n-propyl-6-henzoyloxy-3,4,5,6,7,8-hexahydro-2tlH)-quinolinone and l-n-propyl-6-benzoyloxy-3,4,4a,5,6,7-hexahydro-2(1H)-quinolinone: yield =
2.15 g.
X - 5 0 6 0 B :1145750 Example F
Preparation of trans-dl-2-Acetyl-5-n-propyl-7-ethoxycarbonyl-4,4a,5,6,7,8,8a,9-octahydropyrrolo-[3,4-g]quinoline A mixture of 10 ml. of n-propyl amine and 400 ml. of toluene were cooled in an ice-water bath.
A solution of 16.5 g. of ethyl a-(bromomethyl)-acrylate in 50 ml. of toluene was added thereto in dropwise fashion. The resulting mixture was stirred with cooling for about 25 minutes. Next, a solution of 11 g. of 4-benzoyloxycyclohexanone in 75 ml. of toluene was added in dropwise fashion. This new mixture was heated under a nitrogen atmosphere to refluxing temperature for about 23 hours. The reflux condenser was equipped with a Soxhlet extractor containing a 5A sieve to remove water.
Next the rea~tion mixture was cooled and the cooled mixture filtered. Evaporation of the filtrate yielded a residue comprising a mixture of l-n-propyl-3-ethoxycarbonyl-6-benzoyloxy-1,2,3,4,5,-6,7,8-octahydroquinoline and 1-n-propyl-3-ethoxy-carbonyl-6-benzoyloxy-1,2,3,4,4a,5,~,7-octahydro-quinoline. The residue was dissolved in an ether-chloroform solvent mixture and the resultingsolution saturated with gaseous hydrogen chloride while maintaining the temperatuxe in the range 0-5C. The solve~t was decanted from the crys-talline hydrochloride salts thus formed. The salts 3~ were dissolved in 100 ml. of methanol. 300 ml. of , 11~5750 THF were added and the resulting solution cooled in an ice-water bath. 15 g. o sodium cyanoborohydride were added in portions to the stirred and cooled reaction mixture. After the addition had been completed, the reaction mixture was stirred for another 1.25 hours after which time it was diluted with aqueous sodium bicaxbonate. The aqueous alkaline mixture was extracted several times with ethyl acetate. The ethyl acetate extracts were combined and the combined extracts washed with saturated aqueous sodium chloride solution and then dried. Evaporation of the solvent yielded trans-dl-l-n-propyl-3-ethoxycarbonyl-6-benzoyloxydeca-hydroquinoline. The compound was dissolved in a mixture of 400 ml. of methanol and 100 ml. of 2N
aqueous sodium hydroxide. This mixture was stirred at ambient temperature under a nitrogen atmosphere for 64 hours after which time the volatile con-stituents were removed by evaporation in vacuo. The re~ulting residue was suspended in 800 ml. of ethanol and 15 ml. of 12N aqueous hydrochloric acid.
The esterification mixture was heated to refluxing temperature and about 300 ml. of solvent removed by distillation. 300 ml. of additional ethanol were added and the reaction mix~ure heated to refluxing temperature for 26 hours in an apparatus equipped with a Soxhlet trap containing a 3A sieve. The reaction mixture was cooled, diluted with aqueous sodium bicarbonate and the alkaline mixture ex-tracted several times with chloroform. The chloro-11~5750 form extracts were combined and the combined ex-tracts washed with saturated aqueous sodium chloride and then dried. Evaporation of the chloroform yielded 10.3 g. of a residue which was purifled by chromatography over 150 g. of "Florisil~ using chloroform containing increasing (2-10%) of methanol as the eluant. Trans-dl-l-n-propyl-3-ethoxycar-bonyl-6-hydroxydecahydroquinoline formed in the above reaction was obtained from the eluate frac-tions as a purified product.
A solution was prepared from 8.8 g. oftrans-dl-l-n-propyl-3-ethoxycarbonyl-6-hydroxydeca-hydroquinoline and 400 ml. of methylene dichloride.
41 g. of sodium acetate were added. Next, 10.8 g.
o pyridine hydrochloride:chromium trioxide were added and the resulting mixture stirred for about 22 hours. The reaction mixture was filtered and the iltrate concentrated in vacuo. The resulting concentrate was dissolved in chloroform and the chloroform solution chromatographed over 150 g. of "Florisill~using chloroform containing increasing amounts (1-2%) of methanol as the eluant. Fractions shown by thin-layer chromatography to contain tran3-dl-l-n-propyl-3-ethoxycarbonyl-6-oxodeca-hydroquinoline formed in the above reaction werecombined and the solvent removed from the combined extracts to yield 3.48 g. of the 6-oxo compound as a residue. The 6-oxo compound was dissolved in 100 ml. of toluene containing an added 25 ml. of the dimethylacetal of dimethylformamide. The resulting ~1145750 ~-50~0~
mixture was heated to refluxing temperature under a nitrogen atmosphere for 44 hours and was then allowed to remain at room temperature for an additional 4 days. Volatile constituents were S removed by evaporation in vacuo and the residue, comprising trans-dl-l-n-propyl-3-ethoxycarbonyl-6-oxo-7-(dimethylaminomethylene)decahydroquinoline formed in the above reaction, was purified ~y chromatographing a chloroform solution of the compound ov~er '~Florlsil~ using chloroform containing increasing amounts (2-5%) of methanol as the eluant.
Fractions shown by TLC to contain the desired 7-dimethylaminomethylene compound were combined and the solvent evaporated therefrom in vacuo.
The potassium salt of glycine was prepared by reacting 280 mg. of potassium hydroxide with 370 mg. of glycine in 50 ml. of anhydrous ethanol.
1.3 g. of trans-dl-l-n-propyl-3-ethoxycarbonyl-6-oxo-7-(dimethylaminomethylene)decahydroguinoline were added and the resulting mixture heated under a nitrogen atmosphere to reflux temperature for about 3 hours. The reaction mixture was cooled and the volatile constituents removed by evaporation in vacuo. 50 ml. of acetic anhydride were added to this residue and the resulting mixture heated to reflux temperature under a nitrogen atmosphere for about 45 minutes thus cyclizing, decarboxylating and acetylating all in one step. Again/ the reaction mixture was cooled and the volatile constituents removed by evaporation. In this instance, the X-5060s residue was next diluted with aqueous sodium bi-carbonate and the resulting alkaline aqueous layer extracted with chloroform. The chloroform extract was separated and the separated extract washed with saturated aqueous sodium becarbonate and then dried.
~vaporation of the chloroform yielded a residue which was chromatographed over 35 g. of "Florisil"
using chloroform containing increasing amounts (0-1%) of methanol as the eluant. Fractions shown by TLC to contain the desired trans-dl-2-acetyl-5-n-propyl-7-ethoxycarbonyl-4,4a,5,6,7,8,8a,9-octahydropyrrolo~3,4-g]quinoline formed in the above reaction were combined. The solvent was removed from the combined fractions by evaporation and the resulting residue was dissolved in ether. This ether solution was treated with an excess of maleic acid, also in ether. The resulting precipitate comprising the maleate salt of trans-dl-2-acetyl-5-n-propyl-7-ethoxycarbonyl-4,4a,5,6,7,8,8a,9-octahydropyrrolo[3,4-glquinoline melted at 179-180C. after crystallization from a methanol-ether solvent mixture; yield = 280 mg.
Analysis Calculated: C, 61.59; H, 7.19; N, 6.25;
Found: C, 61.32; H, 6.37; N, 6.53.
690 mg. of trans-dl-2-acetyl-5-n-propyl-7-ethoxycarbonyl-4,4a,5,6,7,8,8a,9-octahydropyrrolo-t3,4-g]quinoline maleate were dissolved in ethanol and this solution added to a solution containing an excess of sodium ethylate in ethanol. The reaction X-50~0s mixture was stirred for 1~2 hour after which time it was diluted with water and the aqueous mixture extracted with chloroform. The chloroform extract was separated, washed with saturated aqueous sodium chloride and then dried. Evaporation of the chloro-form yielded trans-dl-5-n-propyl-7-ethoxycaxbonyl-4,4a,5,6,7,8,8a,9-octahydropyrrolo[3,4-g]quinoline formed in the above reaction. The free base melted at 163-4C. after recrystallization from ethanol.
Analysis calculated: C, 70.31; H, 9.02; N, 9.65 Found: C, 70.22; H, 8.91; N, 9.94.
About 1/2 gram of trans-dl-5-n-propyl-7-ethoxycarbonyl-4,4a,5,6,7,8,8a,9-octahydropyrrolo-[3,4-g]quinoline were dissolved in 75 ml. of tetra-hydrofuran. 1 g. of lithium aluminumhydride was added thereto in small portions. After all of the lithium aluminumhydride had been added, the reaction mixture was stirred for another 2.25 hours after which time the excess lithium aluminumhydride was decomposed by the addition of ethyl acetate and any organometallic salts present decomposed by the addition of 10% aqueous sodium hydroxide. The resulting mixture was diluted with water and the aqueous layer extracted several times with chloro-form. The chloroform extracts were separated and combined and the combined extracts washed with saturated aqueous sodium chloride and then dried.
Evaporation of the solvent yielded as a residue, trans-dl-5-n-propyl-7-hydroxymethyl-4,4a,5,6,7,8,-8a,9-octahydropyrrolo[3,4-g]quinoline, which melted 11~5750 X- 5 0 ~; O B
at 178-180C. after recrystallization from a ethyl ace~ate/ether solvent mixture.
Analysis calculated: C, 72.54; H, 9.74; N, 11.28 Found: C, 72.30; H, 9.73; N, 11.05.
About 0.4 g. cf trans-dl-5-n-propyl-7-hydroxymethyl-4,4a,5,6,7,8,8a,9-octahydropyrrolo-[3,4-g]quinoline were dissolved in 25 ml. of pyridine.
0.5 ml. of methanesulfonyl chloride were added and the resulting mixture stirred for 0.75 hours at room temperature. The reaction mixture was dilu~ed with water and sufficient 14N aqueous a nium hydroxide added to make the reaction mix~ure basic. The a~US mixture was extracted several times with ethyl acetate. The ethyl acetate extracts were combined and the combined extracts washed first with water and then with saturated aqueous ammonium chloride and were then dried. The residue obtained by evaporation of the æolvent was chromatographed over 30 g. of "Plorisil'~' and the chromatogram ~lq~
with chloroform containing increasing quantities ~2-4%) of methanol as the eluant. Fractions shown by thin-layer chromatography to contain the desired methanesulfonyl ester were combined and the solvent re ved ~herefrom ln _acuo. The resulting residue, tran-~-dl-5-n-propyl-7-mesyloxymethyl-4,4a,5,6,7,-8,8a,9-octahydropyrrolo[3,4-g]quinoline was crys-tallized from ethanol; m.p. = 150C. with decomposi-tion.
X-5()60B
FINAL PRODUCTS
Example 1 Preparation of trans-dl-5-Methyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo[3,4-g]ql~inoline from the Corresponding 2-Acetyl Compound.
One and two-tenths grams of trans-dl-2-acetyl-5-methyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo[3, 4-g] quinoline maleate were suspended in 100 ml. of methanol and 10 ml. of 2N aqueous sodium hydroxide were added. The resulting mixture was stirred at room temperature under a nitrogen atmosphere for about 35 minutes and was then diluted with dilute aqueous sodium hydroxide. The resulting alkaline solution was extracted several ~imes with chloroform. The chloroform extracts were combined and the combined extracts washed with saturated aqueous sodium chloride and dried. Evaporatisn of the chloroform yielded 400 ml. of crystalline material melting at 190-6C. with decomposition. A
chloroform solution of the material was then chromatographed o~er 30 g. of "Floris~" using chloro-form containing increasing amounts (2-5%~ of methanol as the eluant. The second major component to be eluted from the column consisted of trans-dl-S-methyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo-13,4-g]quinoline. Fractions containing this compound were combined and the solvent removed from the combined fractions by evaporation. Recrystal-lization of the residue from ether yielded trans-i~s~so ,~-5060B
dl-5-methyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo-t3,4-g]quinoline melting at 200-222C. with decom-position (80 mg.).
Analysis: calc.: C, 75.74 H, 9.53; N, 14.72;
Found : C, 75,8B H, 9.28; N, 14.55.
Following the above procedure, trans-dl-2-acetyl-5-n-propyl-4,4a,5,6,7,8,8a,9-octa-hydro-2H-pyrrolo[3,4-g}quinoline (4.8 g) was hydrolyzed with dilute aqueous sodium hydroxide.
c trans-dl-5-n-Propyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo[3,4-g]quinoline thus prepared was purified by ch~omotography over UFlorisil''using chloroform containing increasing amounts (2-10%) methanol as the eluant. Fractions shown to contain the desired product by TLC were combined and the solvent evaporated therefrom. Recrystallization of the residue from a methanol-ether solvent mixture yielded 245 mg. crystalline trans-dl-5-n-propyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo[3,4-g]quino-Zo line melting at 169-171C. with decomposition; nmr peaks at 52, 384 and 510 cps. (in CDC13).
Analysis: calc.: C, 64.65; H, 7.84; N, 8.38;
~ound : C, 64.40; H, 7.62; N, 8.12.
Example 2 Preparation of trans-dl-5-n-Propyl-4,4a,5,6,7,8,-8a,9-octahydro-2H-pyrrolo[3,4-g]quinoline.
The product trans-dl-2-acetyl-5-n-propyl-4,4a,5,6,7,8,Ba,9-octahydro-2H-pyrrolo[3,4-g]quinoline (from Example B~ was dissolved in 20 ml. of methanol 3o . . ' .
.
.
to which was added 3 ml. of ZN aqueous sodium hydroxide. This reaction mixture was stirred at ambient temperature under a nitrogen atmosphere for 65 min. The reaction mixture was diluted with water and the diluted mixture extracted several times with chloroform. The chloroform extracts were combined and the combined extracts washed with saturated aqueous sodium chloride and then dried. Evaporation of the chloroform yielded a residue which was shown to contain one major spot by TLC. An ether solution of the xesidue, comprising trans-dl-5-n-propyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo[3,4-g]quino-line formed in the above reaction, was treated with an excess of maleic acid in ether solution, thus forming the maleate salt of the base. The maleate salt was separated by filtration and recrystallized from an ether-methanol solvent mixture. trans-dl-5-n-Propyl-4,4a,5,6,7,8,8a,9-octahydro-2H-pyrrolo-~3,4-g]quinoline maleate thus prepared melted 168-170C, with decomposition; yield - 215 mg.
Example 3 The mesylate ester (prepared in Example F) can be reacted with the sodium salt of methyl-mercaptan to yield trans-dl-5-n-propyl-7-methyl-mercaptomethyl-4,4a,5,6,7,8,8a,9-octahydropyrrolo-13,4-g]quinoline.
As evidence of the utility of the compounds of formula I, it has been found that they affect turning behavior in rats in a test procedure , . ~ - - ~ .
designed to uncover compounds useful for the treatment of Parkinsonism utilizing 6-hydroxy-dopamine-lesioned rats. In this test, nigro-neostriatal-lesioned rats are employed, as prepared by the procedure of Ung~erstedt and Arbuthnott, ~rain Res, 24, 485 ~1970). A compound having dopamine agonist activity causes the rats to turn in circles contralateral to the side of the lesion. After a latency period, which varies from compound to compound, the number of turns is ~ounted over a 15-minute period.
Results obtained from testing representa-tive compounds of formula I in the rat turning test are set forth in Table 1 below. The compounds were dissolved in water and the aqueous solution injected into the rat by the intraperitoneal route at a dose level of 1 mg/kg. In the table, column 1 gives the name of the compound, column 2, percent of test animals exhibiting turning behavior, and column 3, avexage number of turns observed in first 15 minutes after end of latency period.
q) O
a ~1 0 ~ C h o D;-r~-r~ ~ O
~ ~ ~ _~
O ~ ~
~ E~ m ~P ~
~1 _~ ~ Q) 1--.a E~ U~ O
O
~a I ~ ~1 ` ~
~ _~ I O c Q, O 1~ rl C~ O ~ ~
~ . ~ o ~
U C ~ I
I 0~ I ~1 O U~ o I, ~ I (a a~
'O ~ U-~
~ I 1~ _1 1 0--~
Z ~ C~ C I ~
h , , The compounds of formula I are also useful as prolactin inhibitors and as such they can be employed in the treatment of inappropriate lactation such as postpartum lactation and galac-torrhea. As evidence of their utility in thetreatment of diseases such as those in which it is desirable to reduce the prolactin level, the com-pounds of formula I have been shown to inhibit prolactin according to the following procedure.
Adult male rats of the Spraque-Dawley strain weighing about 200 g. were housed in an air-conditioned room with controlled lighting (lights on 6 a.m. - 8 p.m.)-and fed lab chow and water ad libitum. Each rat received an intra-peritoneal injection of 2.0 mg. of reserpine in aqueous ~uspension 18 hours before administration of the test drug. The purpose of the reserpine was to keep prolactin levels uniformly elevated. The compounds under test were disQolved in 10 percent ethanol, and were injected intraperitoneally at doses of 0.5 and 5 mg/kg. Each compound was ad-ministered at each dose level to a group of 10 rats, and a control group of 10 intact males received an equivalent amount of 10 percent ethanol. One hour after treatment, all rats were killed by decapita-tion, and 150 ~1 aliquots of serum were assayed for prolactin.
The difference between the prolactin level of the treated rats and prolactin level of the control rat~, divided by the prolactin level of the control rats gives the percent inhibition of prolactin secretion attributable to the compounds of formula I. These inhibition percentages are given in Table 2 below. In the table, column 1 gives the name of the compound; and columns 2 and 3 ! the percent prolactin inhibition at the 0.5 and 5 mg/kg dose levels.
,..
1~5750 .
o ~:
S ~ ~
a ~ Ll o ~ ~ a~ cn O U~
.,~
C) ~ .Y
O ~ I
I
~ D.
a~ ~ In _~ C Q
~ U
E~
P.
0, O O
' ~ `
l O ~ `~ _ o :~ O S Q~
O ~ ~ C ~: ~1 C
l~ J- rl ~ S-rl O C O O ~:~ O
C.~ I I C I
~ 0~ Ul O-r~
q~
O
~ 00 a~ I ' ~ I ~
~ U~ tD I ~n co I
:Z
. i~45750 In using the compounds of formula I
to inhibit prolactin secretion or to treat Parkinson's syndrome or for other pharmacologic action, a com-pound according to formula I above in which R2 is S Cl-C3 alkyl or allyl and Rl is H or Cl-C3 alkyl, or a salt thereof with a pharmaceutically-acceptable acid, is administered to a subject suffering from Parkin-sonism or in need of having his prolactin level reduced in an effective amount to treat Parkinsonism or to reduce prolactin. Oral administration is preferred. If parenteral administration is used, the injection is preferably by the subcutaneous route using an appropriate pharmaceutical formulation.
Other modes of parenteral administration such as intraperitoneal, intramuscular, or intra~enous routes are equally effective. In particular, wi~h intra-venous or intramuscular administration, a water soluble pharmaceutically-acceptable salt is employed.
For oral administration, the compound either as the free base or in the form of a ~alt thereof can also be mixed w$th standard pharmaceutical excipients and loaded into empty telescoping gelatin capsules or pressed into tablets. For oral administration, the compound either as the free base or in the form of a salt thereof, can also be mix~d with standard pharmaceutical excipients and loaded into empty telescoping gelatin capsules or pressed into tablets.
~he oral dosage range is from about 0.01 to 10 mg. to 10 mg./kg. of mammalian weight and the parenteral dose range from about 0.0025 to 2.5 mg./kg. Intra-` 114S7SO
peritoneal dosages of 10-30 mg./kg. of trans-dl-5-n-propyl-4,4a,5,6,7,8,8a,9-octahydro-pyrrolo-13,4-g]-quinoline dihydrochloride resulted in no - deaths, but dosages of 100-300 mg./kg. were fatal, indicating an LD50 in the range 30-100 mg./kg.
Claims (2)
1. A process for preparing an inter-mediate compound of the formula Ic wherein R1 is H or (C1-C3)alkyl-CO;
R2 is H, benzyl or C1-C3 alkyl; and R3 is H, COO(C1-C3)alkyl, COOH, or CH2X
wherein X1 is OH, Cl, OSO2(C1-C3)alkyl, OSO2tolyl, or OSO2phenyl;
with the proviso that both R1 and R3 can not be H when R2 is C1-C3 alkyl; and their salts, which comprises reacting a compound of the general formula wherein R4 is H or COOZ' where Z' is (C1-C2)alkyl or phenyl substituted (C1-C2)alkyl, with potassium glycinate followed by an anhydride gives a compound of formula Ic where R1 is (C1-C3)alkyl-CO;
optionally followed by hydrolysis when is (C1-C3)alkyl-CO to provide the compounds of formula Ic where R1 is H;
optionally followed by reduction with a metal hydride when R3 of formula Ic is COOZ' to obtain the compounds of Ic where R3 is CH2OH;
optionally followed by reacting the compounds of formula Ic wherein R3 is CH2OH with a nucleophilic reagent, such as Br, Cl, or OSO2(C1-C3)-alkyl, OSO2phenyl or OSO2-tolyl halides.
R2 is H, benzyl or C1-C3 alkyl; and R3 is H, COO(C1-C3)alkyl, COOH, or CH2X
wherein X1 is OH, Cl, OSO2(C1-C3)alkyl, OSO2tolyl, or OSO2phenyl;
with the proviso that both R1 and R3 can not be H when R2 is C1-C3 alkyl; and their salts, which comprises reacting a compound of the general formula wherein R4 is H or COOZ' where Z' is (C1-C2)alkyl or phenyl substituted (C1-C2)alkyl, with potassium glycinate followed by an anhydride gives a compound of formula Ic where R1 is (C1-C3)alkyl-CO;
optionally followed by hydrolysis when is (C1-C3)alkyl-CO to provide the compounds of formula Ic where R1 is H;
optionally followed by reduction with a metal hydride when R3 of formula Ic is COOZ' to obtain the compounds of Ic where R3 is CH2OH;
optionally followed by reacting the compounds of formula Ic wherein R3 is CH2OH with a nucleophilic reagent, such as Br, Cl, or OSO2(C1-C3)-alkyl, OSO2phenyl or OSO2-tolyl halides.
2. An intermediate compound of the formula Ic wherein R1 is H or (C1-C3)alkyl-CO;
R2 is H, benzyl or C1-C3 alkyl; and R3 is H, COO(C1-C3)alkyl, COOH, or CH2X1 wherein X1 is QH, Cl, OSO2(C1-C3)alkyl, OSO2tolyl, or OSO2phenyl;
with the proviso that both R1 and R3 can not be H when R2 is C1-C3 alkyl; and their salts, whenever prepared by the process of claim 1 or an obvious chemical equivalent thereof.
R2 is H, benzyl or C1-C3 alkyl; and R3 is H, COO(C1-C3)alkyl, COOH, or CH2X1 wherein X1 is QH, Cl, OSO2(C1-C3)alkyl, OSO2tolyl, or OSO2phenyl;
with the proviso that both R1 and R3 can not be H when R2 is C1-C3 alkyl; and their salts, whenever prepared by the process of claim 1 or an obvious chemical equivalent thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000403807A CA1145750A (en) | 1979-01-22 | 1982-05-26 | Octahydro-2h-pyrrolo (3,4,-g) quinolines |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US506279A | 1979-01-22 | 1979-01-22 | |
| US5,062 | 1979-01-22 | ||
| US06/031,642 US4235909A (en) | 1979-04-19 | 1979-04-19 | Octahydro-2H-pyrrolo[3,4-g]quinolines |
| US31,642 | 1979-04-19 | ||
| CA330,551A CA1131227A (en) | 1979-01-22 | 1979-06-26 | Octahydro-2h-pyrrolo (3,4,-g) quinolines |
| CA000403807A CA1145750A (en) | 1979-01-22 | 1982-05-26 | Octahydro-2h-pyrrolo (3,4,-g) quinolines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1145750A true CA1145750A (en) | 1983-05-03 |
Family
ID=27426159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000403807A Expired CA1145750A (en) | 1979-01-22 | 1982-05-26 | Octahydro-2h-pyrrolo (3,4,-g) quinolines |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA1145750A (en) |
-
1982
- 1982-05-26 CA CA000403807A patent/CA1145750A/en not_active Expired
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0013787B1 (en) | Octahydro pyrazolo (3,4-g)quinolines, process for their preparation and pharmaceutical compositions containing them | |
| US4235909A (en) | Octahydro-2H-pyrrolo[3,4-g]quinolines | |
| US4950759A (en) | Substituted 1,7-annelated 1H-indazoles | |
| US4230861A (en) | 1-And/or 7-substituted-6-hydroxy (or oxo)-3-decahydroquinoline carboxylic acids | |
| CA1131227A (en) | Octahydro-2h-pyrrolo (3,4,-g) quinolines | |
| CA1145750A (en) | Octahydro-2h-pyrrolo (3,4,-g) quinolines | |
| US4311844A (en) | Octahydro-2H-pyrrolo[3,4,-g]quinolines | |
| US4367231A (en) | Method of using octahydro pyrazolo[3,4-g]quinolines | |
| US4282362A (en) | Octahydro-2H-pyrrolo[3,4-g]quinolines | |
| CA1292742C (en) | Octahydro-oxazolo (4,5-g)quinolines | |
| IE52873B1 (en) | Imidazo(1,2-a)quinoline derivatives | |
| JPS6368568A (en) | P-aminophenol derivative | |
| SU1017167A3 (en) | Process for preparing d-5-acetamido-4,5,6,7-tetrahydro-2h-benzo(c)pyrrole | |
| CA1136629A (en) | Octahydro pyrazolo (3,4,-g) quinolines | |
| US4235776A (en) | Tetrahydro-2H-benzo[c]pyrroles | |
| KR830000586B1 (en) | Method for preparing octahydro-2H-pyrrolo [3, 4-g] quinoline | |
| CA1136141A (en) | Octahydro pyrazolo (3,4,-g) quinolines | |
| EP0014792B1 (en) | Tetrahydro-2h-benzo(c)pyrroles, their preparation, pharmaceutical compositions containing them and the compounds for use as therapeuticals | |
| HU180234B (en) | Process for producing oktahydro-pyrasolo-aracket-3,4-g-bracket closed-quinolines | |
| CA1133487A (en) | Octahydro pyrazolo (3,4-g) quinolines | |
| IE48395B1 (en) | Octahydro pyrazolo(3,4-g)quinolines | |
| KR830000273B1 (en) | Method for preparing octahydropyrazolo [3,4-g] quinoline | |
| CA1136144A (en) | Octahydro pyrazolo (3,4,-g) quinolines | |
| IE48649B1 (en) | Tetrahydro-2h-benzo(c)pyrroles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |